<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Post‐mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes - Verma, R - 2023 | Cochrane Library</title> <meta content="Post‐mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes - Verma, R - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014463.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Post‐mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes - Verma, R - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014463.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD014463.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Post‐mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes" name="citation_title"/> <meta content="Rashmi Verma" name="citation_author"/> <meta content="Lancashire Teaching Hospitals NHS Foundation Trust" name="citation_author_institution"/> <meta content="Mihir Chandarana" name="citation_author"/> <meta content="HEE East Midlands" name="citation_author_institution"/> <meta content="Jessica Barrett" name="citation_author"/> <meta content="University of Cambridge" name="citation_author_institution"/> <meta content="Carmel Anandadas" name="citation_author"/> <meta content="Christie NHS Foundation Trust" name="citation_author_institution"/> <meta content="Sreekumar Sundara Rajan" name="citation_author"/> <meta content="University Hospitals Birmingham NHS Foundation Trust" name="citation_author_institution"/> <meta content="sreekumar.sundararajan2@uhb.nhs.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD014463.pub2" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/06/16" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014463.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014463.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014463.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Breast Neoplasms [drug therapy, radiotherapy, surgery]; Combined Modality Therapy; Lymph Nodes [pathology]; Mastectomy; *Neoplasm Recurrence, Local" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014463.pub2&amp;doi=10.1002/14651858.CD014463.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014463.pub2&amp;doi=10.1002/14651858.CD014463.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014463.pub2&amp;doi=10.1002/14651858.CD014463.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014463.pub2&amp;doi=10.1002/14651858.CD014463.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014463.pub2&amp;doi=10.1002/14651858.CD014463.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014463.pub2&amp;doi=10.1002/14651858.CD014463.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014463.pub2&amp;doi=10.1002/14651858.CD014463.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014463.pub2&amp;doi=10.1002/14651858.CD014463.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014463.pub2&amp;doi=10.1002/14651858.CD014463.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014463.pub2&amp;doi=10.1002/14651858.CD014463.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014463.pub2&amp;doi=10.1002/14651858.CD014463.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014463.pub2&amp;doi=10.1002/14651858.CD014463.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014463.pub2&amp;doi=10.1002/14651858.CD014463.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014463.pub2&amp;doi=10.1002/14651858.CD014463.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014463.pub2&amp;doi=10.1002/14651858.CD014463.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014463.pub2&amp;doi=10.1002/14651858.CD014463.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014463.pub2&amp;doi=10.1002/14651858.CD014463.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014463.pub2&amp;doi=10.1002/14651858.CD014463.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014463.pub2&amp;doi=10.1002/14651858.CD014463.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014463.pub2&amp;doi=10.1002/14651858.CD014463.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014463.pub2&amp;doi=10.1002/14651858.CD014463.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014463.pub2&amp;doi=10.1002/14651858.CD014463.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014463.pub2&amp;doi=10.1002/14651858.CD014463.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="8ranHhTh";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD014463\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD014463\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014463\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014463\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","pt","ko","ms","hr","fr","hu","zh_HANS","zh_HANT","th","fa","id","ro"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD014463.pub2",title:"Post\\u2010mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes",firstPublishedDate:"Jun 16, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Breast Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=8ranHhTh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014463.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014463.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD014463.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD014463.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014463.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD014463.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ro&quot;,&quot;title&quot;:&quot;Sumar&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD014463.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD014463.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD014463.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD014463.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8800 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD014463.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014463.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014463.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014463.pub2/full#CD014463-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014463.pub2/full#CD014463-sec-0066"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014463.pub2/full#CD014463-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014463.pub2/full#CD014463-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014463.pub2/full#CD014463-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014463.pub2/full#CD014463-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014463.pub2/full#CD014463-sec-0040"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014463.pub2/full#CD014463-sec-0060"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014463.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014463.pub2/appendices#CD014463-sec-0071"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014463.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014463.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD014463.pub2/media/CDSR/CD014463/supinfo/CD014463-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD014463.pub2/media/CDSR/CD014463/supinfo/CD014463-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014463.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014463.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014463.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014463.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014463.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD014463.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Post‐mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014463.pub2/information#CD014463-cr-0004">Rashmi Verma</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014463.pub2/information#CD014463-cr-0005">Mihir Chandarana</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014463.pub2/information#CD014463-cr-0006">Jessica Barrett</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014463.pub2/information#CD014463-cr-0007">Carmel Anandadas</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014463.pub2/information#CD014463-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>Sreekumar Sundara Rajan</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/information/en#CD014463-sec-0083">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 16 June 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD014463.pub2">https://doi.org/10.1002/14651858.CD014463.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD014463-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014463-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD014463-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014463-abs-0020">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014463-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD014463-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD014463-abs-0004">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD014463-abs-0018">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD014463-abs-0015">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD014463-abs-0001" lang="en"> <section id="CD014463-sec-0001"> <h3 class="title" id="CD014463-sec-0001">Background</h3> <p>Continual improvement in adjuvant therapies has resulted in a better prognosis for women diagnosed with breast cancer. A surrogate marker used to detect the spread of disease after treatment of breast cancer is local and regional recurrence. The risk of local and regional recurrence after mastectomy increases with the number of axillary lymph nodes affected by cancer. There is a consensus to use radiotherapy as an adjuvant treatment after mastectomy (postmastectomy radiotherapy (PMRT)) in women diagnosed with breast cancer and found to have disease in four or more positive axillary lymph nodes. Despite data showing almost double the risk of local and regional recurrence in women treated with mastectomy and found to have one to three positive lymph nodes, there is a lack of international consensus on the use of PMRT in this group. </p> </section> <section id="CD014463-sec-0002"> <h3 class="title" id="CD014463-sec-0002">Objectives</h3> <p>To assess the effects of PMRT in women diagnosed with early breast cancer and found to have one to three positive axillary lymph nodes. </p> </section> <section id="CD014463-sec-0003"> <h3 class="title" id="CD014463-sec-0003">Search methods</h3> <p>We searched the Cochrane Breast Cancer Group's Specialised Register, CENTRAL, MEDLINE, Embase, the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) and ClinicalTrials.gov up to 24 September 2021. </p> </section> <section id="CD014463-sec-0004"> <h3 class="title" id="CD014463-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs). The inclusion criteria included women diagnosed with breast cancer treated with simple or modified radical mastectomy and axillary surgery (sentinel lymph node biopsy (SLNB) alone or those undergoing axillary lymph node clearance with or without prior SLNB). We included only women receiving PMRT using X‐rays (electron and photon radiation), and we defined the radiotherapy dose to reflect what is currently being recommended (i.e. 40 Gray (Gy) to 50 Gy in 15 to 25/28 fractions in 3 to 5 weeks. The included studies did not administer any boost to the tumour bed. In this review, we excluded studies using neoadjuvant chemotherapy as a supportive treatment before surgery. </p> </section> <section id="CD014463-sec-0005"> <h3 class="title" id="CD014463-sec-0005">Data collection and analysis</h3> <p>We used Covidence to screen records. We collected data on tumour characteristics, adjuvant treatments and the outcomes of local and regional recurrence, overall survival, disease‐free survival, time to progression, short‐ and long‐term adverse events and quality of life. We reported on time‐to‐event outcome measures using the hazard ratio (HR) and subdistribution HR. We used Cochrane's risk of bias tool (RoB 1), and we presented overall certainty of the evidence using the GRADE approach. </p> </section> <section id="CD014463-sec-0006"> <h3 class="title" id="CD014463-sec-0006">Main results</h3> <p>The RCTs included in this review were subgroup analyses of original RCTs conducted in the 1980s to assess the effectiveness of PMRT. Hence, the type and duration of adjuvant systemic treatments used in the studies included in this review were suboptimal compared to the current standard of care. </p> <p>The review involved three RCTs with a total of 829 women diagnosed with breast cancer and low‐volume axillary disease. Amongst the included studies, only a single study pertained to the modern‐day radiotherapy practice. The results from this one study showed a reduction of local and regional recurrence (HR 0.20, 95% confidence interval (CI) 0.13 to 0.33, 1 study, 522 women; low‐certainty evidence) and improvement in overall survival with PMRT (HR 0.76, 95% CI 0.60 to 0.97, 1 study, 522 women; moderate‐certainty evidence). One of the other studies using radiotherapy techniques that do not reflect modern‐day practice reported on disease‐free survival in women with low‐volume axillary disease (subdistribution HR 0.63, 95% CI 0.41 to 0.96, 1 study, 173 women). None of the included studies reported on PMRT side effects or quality‐of‐life outcome measures. </p> </section> <section id="CD014463-sec-0007"> <h3 class="title" id="CD014463-sec-0007">Authors' conclusions</h3> <p>Based on one study, the use of PMRT in women diagnosed with breast cancer and low‐volume axillary disease indicated a reduction in locoregional recurrence and an improvement in survival. There is a need for more research to be conducted using modern‐day radiotherapy equipment and methods to support and supplement the review findings. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD014463-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014463-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD014463-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD014463-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014463-abs-0021">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014463-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD014463-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/hu#CD014463-abs-0012">Magyar</a> </li> <li class="section-language"> <a class="" href="full/id#CD014463-abs-0022">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ko#CD014463-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD014463-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD014463-abs-0005">Português</a> </li> <li class="section-language"> <a class="" href="full/ro#CD014463-abs-0023">Română</a> </li> <li class="section-language"> <a class="" href="full/th#CD014463-abs-0019">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD014463-abs-0016">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD014463-abs-0017">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD014463-abs-0002" lang="en"> <h3>Is X‐ray treatment (radiotherapy) after removal of breast tissue (mastectomy) better than no X‐ray treatment in women diagnosed with breast cancer that has spread to one to three armpit lymph nodes? </h3> <p><b>Key message:</b> </p> <p>• Radiotherapy after breast removal (also known as mastectomy) may reduce cancer returning to the chest wall and in the nearby lymph nodes. </p> <p>• Radiotherapy probably improves survival in women diagnosed with breast cancer who have 1 to 3 involved lymph nodes. </p> <p>• We found one large ongoing international study that should provide more evidence when it has finished. </p> <p><b>What is breast cancer?</b> </p> <p>Breast cancer is the most common form of cancer affecting women. The improvements in treatments (anticancer drugs) that target the entire body over the last 2 decades have resulted in fewer cancer‐related deaths. The development of recurrence in the chest wall and nearby lymph nodes after the initial treatment of breast cancer can increase the risk of cancer spreading. It has been shown that the risk of cancer recurring in the chest wall and nearby lymph nodes was more than doubled in women diagnosed with 1 to 3 positive axillary lymph nodes compared to node‐negative disease. </p> <p><b>What is the role of additional supportive treatment in the management of breast cancer?</b> </p> <p>Radiotherapy is a well‐established supportive targeted treatment that reduces region‐specific recurrence after surgery in women diagnosed with breast cancer. However, researchers over the last 2 to 3 decades were not able to show without doubt that the reduction in recurrence central to a location with radiotherapy leads to fewer breast cancer‐related deaths. </p> <p><b>When should radiotherapy be used?</b> </p> <p>Researchers agree about the use of radiotherapy after mastectomy in women with high‐risk breast cancer characteristics, like large tumour size (larger than 5 cm) and 4 or more axillary lymph nodes affected with breast cancer. However, scientists are still unsure about the role of radiotherapy after mastectomy in women with lower‐risk characteristics who are found to have 1 to 3 axillary lymph nodes affected by breast cancer. </p> <p><b>What did the review authors want to find out?</b> </p> <p>For women diagnosed with breast cancer and found to have 1 to 3 lymph nodes affected by cancer, we asked: </p> <p>• Does radiotherapy after breast removal reduce the occurrence of region‐based recurrence compared to no radiotherapy? </p> <p>• Is there any survival advantage in women undergoing PMRT compared to those not having radiotherapy? </p> <p>• What are the short‐ and long‐term unwanted effects of PMRT?</p> <p>• Is there any difference in the quality of life for women undergoing radiotherapy compared to those with no radiotherapy? </p> <p><b>What did we do?</b> </p> <p>We searched for studies that compared radiotherapy after mastectomy against no radiotherapy in women diagnosed with breast cancer with 1 to 3 involved axillary lymph nodes. Once we identified the relevant studies, we compared and summarised the results. We have also assessed and rated our confidence in the presented evidence based on the study methods and the number of women who participated in the studies. </p> <p><b>What did we find?</b> </p> <p>We found 3 studies with 725 women; 355 women received radiotherapy, and 370 did not. The largest study was conducted in Denmark and involved 552 women. The remaining two studies were conducted in Sweden and involved 104 premenopausal and 173 postmenopausal women. Only the Danish study administered radiotherapy using methods that are comparable to modern‐day practice. All the studies followed the women for 15 years or more. The studies were funded by independent charitable organisations with no funding from private or pharmaceutical companies. </p> <p><b>Main results</b> </p> <p>The use of radiotherapy compared to no radiotherapy in women diagnosed with breast cancer who have 1 to 3 involved axillary lymph nodes: </p> <p>• may lead to a reduction in the regional recurrence; and</p> <p>• probably improves survival by 24% in women.</p> <p>We did not identify any study that reliably assessed the effect of radiotherapy after mastectomy on disease‐free survival, short‐ or long‐term unwanted effects and quality of life in breast cancer survivors. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>Our confidence in the evidence is low to moderate for 3 main reasons.</p> <p>First, the studies we included took place before many modern advancements in breast cancer treatment. Second, we could only interpret results from one study that used updated radiotherapy techniques. Finally, the studies we used did not provide all of the information we wanted regarding the long‐term effectiveness of treatment in participants. </p> <p><b>How up to date is the evidence?</b> </p> <p>The evidence presented here is up to date to September 2021.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD014463-sec-0066" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD014463-sec-0066"></div> <h3 class="title" id="CD014463-sec-0067">Implications for practice</h3> <section id="CD014463-sec-0067"> <p>Based on one study, this review showed a reduction in locoregional recurrence and improvement in overall survival with the use of postmastectomy radiotherapy (PMRT) amongst women diagnosed with breast cancer and found to have one to three positive axillary lymph nodes. There is a lack of published evidence to draw conclusions on the side effects and quality of life outcome measures after PMRT. </p> </section> <h3 class="title" id="CD014463-sec-0068">Implications for research</h3> <section id="CD014463-sec-0068"> <p>There is currently a paucity of evidence within the literature to evaluate the effectiveness of PMRT in women diagnosed with breast cancer and low‐volume axillary disease. Currently, there is a single ongoing multicentre international randomised study that is trying to address this question and could add further insight into the role of PMRT in women with low‐volume axillary disease. Despite this, it is likely that further studies in the future will still be needed to address the same question with updated current radiotherapy techniques to truly evaluate the benefit of treatment in view of the reduction in late adverse effects these newer techniques have to offer. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD014463-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD014463-sec-0008"></div> <div class="table" id="CD014463-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) compared to no PMRT in women with breast cancer and one to three positive lymph nodes</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Postmastectomy radiotherapy (PMRT) compared to no PMRT in women with breast cancer and one to three positive lymph nodes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women with breast cancer and one to three positive lymph nodes<br/><b>Setting:</b> Postoperative follow‐up<br/><b>Intervention:</b> postmastectomy radiotherapy (PMRT)<br/><b>Comparison:</b> no PMRT </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no PMRT</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with postmastectomy radiotherapy (PMRT)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Local and regional recurrence (LRR)<br/>follow‐up: 15 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>10‐year risk of LRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.20</b><br/>(0.13 to 0.33)<br/>[Local and regional recurrence] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>552<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>255 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b><br/>(38 to 93) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival (OS)<br/>follow‐up: 25 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>10‐year risk of death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.76</b><br/>(0.60 to 0.97)<br/>[Overall survival] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>552<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>403 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>324 per 1000</b><br/>(266 to 394) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease‐free survival (DFS)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No randomised controlled trials reported on disease‐free survival in PMRT women with low‐volume axillary disease. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to progression</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No randomised controlled trials reported time to progression in PMRT women with low‐volume axillary disease. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No randomised controlled trials evaluated PMRT short‐term adverse events like erythema, hyperpigmentation and breast oedema. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No randomised controlled trials evaluated the long‐term adverse events of PMRT like lymphoedema, cardiac toxicity, pulmonary toxicity, bone necrosis and development of secondary radiation‐induced cancers. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life (QoL)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No randomised controlled trials measured or reported on the quality of life indicators after PMRT. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>HR:</b> hazard Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_433754310228759346" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_433754310228759346</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Estimated from the no‐PMRT group published Kaplan‐Meier curve in one study (Overgaard 2007).<br/><sup>b</sup> Downgraded quality of evidence by one level due to "serious concern about the risk of bias" originating from inadequate random sequence generation, lack of allocation concealment and not attempting to blind the assessors. <br/><sup>c</sup> Downgraded quality of evidence by one level due to the "serious imprecision" because of uncertainty in confidentially determining the spread of the observed effect in the PMRT group. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD014463-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD014463-sec-0009"></div> <section id="CD014463-sec-0010"> <h3 class="title" id="CD014463-sec-0010">Description of the condition</h3> <p>Breast cancer is the most common malignancy to affect women; in 2018, more than 2 million breast cancer cases were diagnosed globally, which accounted for 24.5% of all cancers in women (<a href="./references#CD014463-bbs2-0026" title="BrayF , FerlayJ , SoerjomataramI , SiegelRL , TorreLA , JemalA . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians2018;68(6):394-424.">Bray 2018</a>). The American Cancer Society has estimated that in 2020 around 276,480 new cases of invasive breast cancer will be diagnosed in the USA, with an estimated 42,690 deaths (<a href="./references#CD014463-bbs2-0069" title="SiegelRL , MillerKD , JemalA . Cancer statistics, 2020. CA: A Cancer Journal for Clinicians2020;70(1):7-30.">Siegel 2020</a>). Early diagnosis through screening and advancements in supportive (adjuvant) treatments over the years have resulted in improved outcomes for breast cancer survivors. This is reflected in the 1.5% average reduction in the age‐adjusted death rate per year between 2008 and 2017 in the USA compared to a 0.3% average rise of age‐adjusted new cases in the same period (<a href="./references#CD014463-bbs2-0067" title="Surveillance, Epidemiology, and End Results Program - National Cancer Institute, 2020. Female Breast Cancer - Cancer stat facts. Available from seer.cancer.gov/statfacts/html/breast.html (accessed July 2021).">SEER 2020</a>). </p> <p>The development of local and regional recurrence of breast cancer is a dreaded outcome that affects 5% to 15% of women diagnosed with breast cancer after mastectomy (removal of all breast tissue) and radiotherapy (<a href="./references#CD014463-bbs2-0036" title="Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet2014;383(9935):2127-35.">EBCTCG 2014</a>). Local and regional recurrence after primary breast cancer treatment is typically associated with an increased risk of concurrent and future spread of cancer elsewhere in the body (<a href="./references#CD014463-bbs2-0075" title="Van TienhovenG , VoogdAC , PeterseJL , NielsenM , AndersenKW , MignoletF , et al. Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG- 82TM). European Journal of Cancer1999;35(1):32-8.">Van Tienhoven 1999</a>). The 10‐year relative survival (cancer survival in the absence of other causes of death) after local and regional recurrence has been shown to be in the region of 25% to 50% even after attempts to remove the cancer recurrence (<a href="./references#CD014463-bbs2-0029" title="ChagparA , KuererHM , HuntKK , StromEA , BuchholzTA . Outcome of treatment for breast cancer patients with chest wall recurrence according to initial stage: implications for post-mastectomy radiation therapy. International Journal of Radiation Oncology, Biology, Physics2003;57(1):128-35.">Chagpar 2003</a>; <a href="./references#CD014463-bbs2-0075" title="Van TienhovenG , VoogdAC , PeterseJL , NielsenM , AndersenKW , MignoletF , et al. Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG- 82TM). European Journal of Cancer1999;35(1):32-8.">Van Tienhoven 1999</a>). The commonest area of local and regional recurrence after mastectomy is the chest wall (53%) followed by lymph nodes above and below the collar bone (26%) and in the armpit (13%) (<a href="./references#CD014463-bbs2-0048" title="KatzA , StromEA , BuchholzTA , ThamesHD , SmithCD , JhingranA , et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. Journal of Clinical Oncology2016;18(15):2817-27.">Katz 2000</a>; <a href="./references#CD014463-bbs2-0053" title="NielsenHM , OvergaardM , GrauC , JensenAR , OvergaardJ . Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. Journal of Clinical Oncology2016;24(15):2268-75.">Nielsen 2006</a>; <a href="./references#CD014463-bbs2-0076" title="WallgrenA , BonettiM , GelberRD , GoldhirschA , Castiglione-GertschM , HolmbergSB , et al. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. Journal of Clinical Oncology2003;21(7):1205-13.">Wallgren 2003</a>). A palpable lump in these sites, painful enlarged lymph nodes and, in some cases, elevated red patches on the chest wall are common symptoms. The risk of local and regional recurrence after mastectomy substantially increases with the number of axillary lymph nodes containing breast cancer. The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) individual participant data meta‐analysis demonstrated that the risk of local and regional recurrence is more than doubled in women who had a mastectomy with one to three lymph nodes affected with cancer compared to node‐negative women with breast cancer (<a href="./references#CD014463-bbs2-0035" title="Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet2005;366(9503):2087-106.">EBCTCG 2005</a>). </p> </section> <section id="CD014463-sec-0011"> <h3 class="title" id="CD014463-sec-0011">Description of the intervention</h3> <p>Breast cancer is a systemic disease, and radiotherapy is a well‐established additional treatment (adjuvant) that aims to reduce local and regional recurrence (<a href="./references#CD014463-bbs2-0038" title="FisherB , DignamJ , WolmarkN , MamounasE , CostantinoJ , PollerW , et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. Journal of Clinical Oncology1998;16(2):441-52.">Fisher 1998</a>; <a href="./references#CD014463-bbs2-0039" title="FisherB , AndersonS , BryantJ , MargoleseRG , DeutschM , FisherER , et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. New England Journal of Medicine2002;347(16):1233-41.">Fisher 2002</a>). Radiotherapy involves radiation treatment using X‐rays or other forms of ionising radiation, and the doses are measured in Gray (Gy). Radiotherapy is administered in fractions to achieve maximum cancer control while attempting to reduce local complications. Up until April 2020, the standard practice in the UK for postmastectomy chest‐wall radiotherapy was 40 Gy in 15 fractions over a period of three weeks based on the evidence from the UK START A and B trials (<a href="./references#CD014463-bbs2-0070" title="The START Trialist Group. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331-41.">START TRIAL A</a>; <a href="./references#CD014463-bbs2-0071" title="The START Trialist Group. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet2008;371(9618):1098-107.">START TRIAL B</a>). Amongst women with node‐positive or high‐risk node‐negative breast cancer, the addition of regional nodal radiotherapy is dependent on risk stratification based on the characteristics of their cancer. The role of regional nodal irradiation has been evaluated in two large randomised controlled trials (RCTs), and both failed to identify any overall survival benefit but did show a significant reduction in breast cancer recurrence (<a href="./references#CD014463-bbs2-0061" title="PoortmansPM , ColletteS , KirkoveC , Van LimbergenE , BudachV , StruikmansH , et al. Internal mammary and medial supraclavicular irradiation in breast cancer. New England Journal of Medicine2015;373(4):317-27.">Poortmans 2015</a>; <a href="./references#CD014463-bbs2-0078" title="WhelanTJ , OlivottoIA , ParulekarWR , AckermanI , ChuaBH , NabidA , et al for the MA20 Study Investigators. Regional nodal irradiation in early-stage breast cancer. New England Journal of Medicine2015;373(4):307-16.">Whelan 2015</a>). In contrast, a Danish population‐based cohort study showed an overall survival benefit of 4% for those women who received radiotherapy to lymph nodes near their breast bone (internal mammary) (<a href="./references#CD014463-bbs2-0072" title="ThorsenLB , OffersenBV , DanøH , BergM , JensenI , PedersenAN , et al. DBCG-IMN: a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. Journal of Clinical Oncology2016;34(4):314-20.">Thorsen 2016</a>). However, due to the lack of conclusive evidence of overall survival benefits in RCTs (<a href="./references#CD014463-bbs2-0045" title="HennequinC , BossardN , Servagi-VernatS , MaingonP , DuboisJB , DatcharyJ , et al. Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy. International Journal of Radiation Oncology, Biology, Physics2013;86(5):860-6.">Hennequin 2013</a>; <a href="./references#CD014463-bbs2-0061" title="PoortmansPM , ColletteS , KirkoveC , Van LimbergenE , BudachV , StruikmansH , et al. Internal mammary and medial supraclavicular irradiation in breast cancer. New England Journal of Medicine2015;373(4):317-27.">Poortmans 2015</a>), regional nodal irradiation is recommended only in people with a high index of suspicion of nodal involvement or confirmed significant axillary nodal metastatic cancer (<a href="./references#CD014463-bbs2-0052" title="National Collaborating Centre for Cancer. Early and locally advanced breast cancer: diagnosis and management. NICE Clinical Guidelines, NG1012018.">NICE 2018</a>). </p> </section> <section id="CD014463-sec-0012"> <h3 class="title" id="CD014463-sec-0012">How the intervention might work</h3> <p>Radiotherapy has been shown to reduce the 10‐year risk of local and regional recurrence by two‐thirds in women affected with breast cancer (<a href="./references#CD014463-bbs2-0033" title="Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. Early Breast Cancer Trialists’ Collaborative Group. New England Journal of Medicine1995;333(22):1444-55.">EBCTCG 1995</a>). However, the improvement in local and regional recurrence has not been shown to translate into a consistent survival advantage. The EBCTCG overview showed that for every 1.5 local and regional recurrences prevented in the first 10 years after radiotherapy, one breast cancer‐specific death could be prevented in 20 years (<a href="./references#CD014463-bbs2-0036" title="Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet2014;383(9935):2127-35.">EBCTCG 2014</a>). The absolute benefit in survival advantage might be much higher if we consider the advances in radiotherapy techniques over the last 20 years (<a href="./references#CD014463-bbs2-0033" title="Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. Early Breast Cancer Trialists’ Collaborative Group. New England Journal of Medicine1995;333(22):1444-55.">EBCTCG 1995</a>; <a href="./references#CD014463-bbs2-0074" title="TruongPT , OlivottoIA , KaderHA , PanadesM , SpeersCH , BertheletE . Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. International Journal of Radiation Oncology, Biology, Physics2005;61(5):1337-47.">Truong 2005</a>). These include methods used to protect the heart, lungs and major blood vessels inside the chest wall from radiotherapy‐induced morbidity and mortality in women with breast cancer. The findings of the EBCTCG overview (<a href="./references#CD014463-bbs2-0034" title="Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet2000;355(9217):1757-70.">EBCTCG 2000</a>) and long‐term outcomes of some seminal RCTs (<a href="./references#CD014463-bbs2-0057" title="OvergaardM , NielsenHM , OvergaardJ . Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&amp;c randomized trials. Radiotherapy and Oncology2007;82(3):247-53.">Overgaard 2007</a>; <a href="./references#CD014463-bbs2-0062" title="RagazJ , OlivottoIA , SpinelliJJ , PhillipsN , JacksonSM , WilsonKS , et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. Journal of the National Cancer Institute2005;97(2):116-26.">Ragaz 2005</a>) were considered by the St Gallen Consensus Guidelines (2009), which recommended postmastectomy radiotherapy (PMRT) for women affected with breast cancer who had a 20% or greater 10‐year risk of local and regional recurrence (<a href="./references#CD014463-bbs2-0041" title="GoldhirschA , IngleJN , GelberRD , CoatesAS , ThürlimannB , SennHJ . Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Annals of Oncology2009;20(8):1319-29.">Goldhirsch 2009</a>). </p> </section> <section id="CD014463-sec-0013"> <h3 class="title" id="CD014463-sec-0013">Why it is important to do this review</h3> <p>Postmastectomy radiotherapy (PMRT) is currently recommended for women with breast cancer who have four or more lymph nodes involved with metastatic cancer. There is still no international consensus on whether to offer PMRT to women with breast cancer and one to three axillary lymph nodes affected with cancer (low‐volume axillary metastatic disease). The National Comprehensive Cancer Network (NCCN) guidelines recommend giving strong consideration to providing PMRT to women with one to three metastatic axillary lymph nodes (<a href="./references#CD014463-bbs2-0065" title="SalernoKE . NCCN guidelines update: evolving radiation therapy recommendations for breast cancer. Journal of the National Comprehensive Cancer Network2017;15(s5):682-4.">Salerno 2017</a>). However, there is currently no risk stratification model based on demographic or cancer characteristics to enable clinicians to make these difficult choices and decisions. Age, location of the tumour in the inner aspect of the breast, nodal ratio (i.e. the number of lymph nodes with cancer versus the total number of lymph nodes removed during axillary surgery), lymphovascular invasion (cancer invading the small blood vessels and lymphatics in the breast tissue) and oestrogen receptor negativity (i.e. an absence of female hormone molecule binding sites on the surface of cancer cells), tumour size and positive resection margins (<a href="./references#CD014463-bbs2-0040" title="GargAK , OhJL , OswaldMJ , HuangE , StormEA , PerkinsGH , et al. Effect of postmastectomy radiotherapy in patients &lt;35 years old with stage II-III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy. International Journal of Radiation Oncology, Biology, Physics2007;69(5):1478-83.">Garg 2007</a>; <a href="./references#CD014463-bbs2-0074" title="TruongPT , OlivottoIA , KaderHA , PanadesM , SpeersCH , BertheletE . Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. International Journal of Radiation Oncology, Biology, Physics2005;61(5):1337-47.">Truong 2005</a>) are some of the variables that have been shown to be predictors of local and regional recurrence in women with PMRT with low‐volume axillary nodal disease. Predictive tools such as the Cambridge PMRT index have been developed to try and select women who benefit from radiotherapy in this setting (<a href="./references#CD014463-bbs2-0051" title="MukeshMB , DukeS , ParasharD , WishartG , ColesCE , WilsonC . The Cambridge post-mastectomy radiotherapy (C-PMRT) index: a practical tool for patient selection. Radiotherapy and Oncology2014;110(3):461-6.">Mukesh 2014 </a>). The predictive role of age was considered by both the NCCN and the European Society of Breast Cancer Specialists, and they recommend PMRT in young women affected with breast cancer and metastasis in one to three axillary lymph nodes (<a href="./references#CD014463-bbs2-0028" title="CardosoF , LoiblS , PaganiO , GraziottinA , PanizzaP , MartincichL , et al. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. European Journal of Cancer2012;48(18):3355-77.">Cardoso 2012</a>; <a href="./references#CD014463-bbs2-0063" title="RechtA , ComenEA , FineRE , FlemingGF , HardenberghPH , HoAY , et al. Postmastectomy radiotherapy: an American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology focused guideline update. Journal of Clinical Oncology2016;34(36):4431-42.">Recht 2016</a>; <a href="./references#CD014463-bbs2-0065" title="SalernoKE . NCCN guidelines update: evolving radiation therapy recommendations for breast cancer. Journal of the National Comprehensive Cancer Network2017;15(s5):682-4.">Salerno 2017</a>). Similarly, the St Gallen breast cancer meeting in 2019 recommended PMRT in triple‐negative breast cancer (i.e. where there is a lack of expression of oestrogen, progesterone and human epidermal growth factor receptor‐2 protein molecule binding sites on the surface of cancer cells) with one to three positive axillary lymph nodes (<a href="./references#CD014463-bbs2-0027" title="BursteinHJ , CuriglianoG , LoiblS , DubskyP , GnantM , PoortmansP , et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Annals of Oncology2019;30(10):1541-57.">Burstein 2019</a>). </p> <p>The Selective Use of Postoperative Radiotherapy aftEr MastectOmy (SUPREMO) Trial is the only ongoing RCT that might shed light on the role of modern adjuvant systemic treatment (antihormonal tablets or chemotherapy) in PMRT for women diagnosed with breast cancer and found to have metastasis in one to three lymph nodes. Since the result of this study is not expected to be published before 2024, this review will try to bridge the gap in the literature by evaluating the long‐term outcomes of published RCTs to address the uncertainty surrounding the use of PMRT in women with breast cancer who have a low volume of axillary lymph node disease. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD014463-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD014463-sec-0014"></div> <p>To assess the effects of PMRT in women diagnosed with early breast cancer and found to have one to three positive axillary lymph nodes. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD014463-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD014463-sec-0015"></div> <section id="CD014463-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD014463-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) evaluating PMRT in women diagnosed with early breast cancer and low‐volume axillary metastatic disease, which is defined as the involvement of cancer cells in one to three axillary lymph nodes after sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND). </p> </section> <section id="CD014463-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included women diagnosed with early breast cancer and found to have one to three positive axillary lymph nodes. This included women who were found to have a macroscopic (≧ 2 mm in size) deposit of cancer in the axillary lymph nodes (macrometastases). We contacted the corresponding study authors to obtain data on macrometastasis if data were missing or described only as part of a subgroup analysis within the published manuscripts. </p> <p>We included women diagnosed with breast cancer treated with mastectomy and SLNB without any further axillary surgery as well as those who were undergoing ALND with or without initial SLNB. We included women who were undergoing either simple or modified radical mastectomy, while we excluded those undergoing radical mastectomy. To improve the generalisability of the results, we included women of all ages and ethnicities, who have been diagnosed with breast cancer, with any tumour size(s) and with any histological types. </p> </section> <section id="CD014463-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included only studies in which radiotherapy was given using X‐rays (photon radiation) and electrons. The total radiation dose administered for treatment should be consistent with the current recommendations (i.e. 40 Gy to 50 Gy in 15 to 25/28 fractions over 3 to 5 weeks). We included studies in which PMRT was given to the ipsilateral chest wall, axilla, supraclavicular fossa, and internal mammary nodes. We excluded studies in which women diagnosed with breast cancer received only intraoperative radiation, brachytherapy or radiotherapy given using gamma rays. </p> <p>We included studies where adjuvant treatments (endocrine, chemotherapy and biological agents) were given to both the intervention and comparison groups. While we included women who were given chemotherapy after mastectomy (adjuvant chemotherapy), we excluded studies that used neoadjuvant chemotherapy, where chemotherapy was given before surgery. Neoadjuvant chemotherapy was usually offered to women diagnosed with large breast cancers and those with multiple positive axillary lymph nodes. It was given with the intention of reducing the size of cancer to facilitate breast‐conserving surgery and aid in the decision‐making of postsurgical adjuvant treatment. In most cases, progression of the disease or poor response to neoadjuvant chemotherapy was the commonest reason for offering mastectomy before or after completion of neoadjuvant chemotherapy. Finally, the pre‐neoadjuvant chemotherapy cancer characteristics mainly guide the decision to give adjuvant radiotherapy to these women with breast cancer. All these factors detract from the main focus of this review, hence we have excluded studies where neoadjuvant chemotherapy was administered. </p> <p>We have compared PMRT in women with early breast cancer with the low‐volume axillary disease to those who did not receive any radiotherapy. </p> </section> <section id="CD014463-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD014463-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD014463-list-0001"> <li> <p>Local and regional recurrence is defined as the duration in years between the treatment of breast cancer and recurrence of breast cancer in the ipsilateral chest wall, axilla, supraclavicular fossa, infraclavicular fossa or internal mammary nodes. We considered local and regional recurrence as the first event after treatment of breast cancer and thereby prior to the development of any systemic recurrence (i.e. recurrence of breast cancer anywhere else in the body other than those sites involved by local and regional recurrence). In this review, when it was not possible to extract results for the time to local and regional recurrence, we attempted to extract the percentage of women who had a local and regional recurrence at 5, 10 and 15 years. </p> </li> </ul> </p> </section> <section id="CD014463-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD014463-list-0002"> <li> <p>Overall survival: defined as the duration between the diagnosis of breast cancer or the date of surgery to the date of death from any cause </p> </li> <li> <p>Disease‐free survival: defined as the duration between the diagnosis of breast cancer or time of surgery to the date of locoregional or systemic recurrence or death, whichever occurs first </p> </li> <li> <p>Time to progression: defined as the duration between the diagnosis of breast cancer or time of surgery to the date of locoregional or systemic recurrence, whichever occurs first </p> </li> <li> <p>Adverse events, including short‐ and long‐term events: Short‐term adverse events will include erythema, hyperpigmentation and breast oedema. Long‐term adverse events will include lymphoedema, cardiac toxicity, pulmonary toxicity, bone necrosis and the development of secondary radiation‐induced cancers. </p> </li> <li> <p>Quality of life: measured using any validated tool(s)</p> </li> </ul> </p> </section> </section> </section> <section id="CD014463-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD014463-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases and registries on 24 September 2021:</p> <p> <ul id="CD014463-list-0003"> <li> <p>The Cochrane Breast Cancer Group's (CBCG's) Specialised Register. Details of the search strategies used by the Group for the identification of studies and the procedure used to code references are outlined in the Group's module (<a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/BREASTCA/frame.html" target="_blank">https://breastcancer.cochrane.org/specialised-register</a>). Studies with the keywords "breast cancer”, “mastectomy”, “radiotherapy”, “radiation therapy”, “post‐operative radiotherapy” and “post‐mastectomy radiotherapy” were extracted and considered for inclusion in the review. </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2021, Issue 9) in the Cochrane Library (searched 24 September 2021). See <a href="./appendices#CD014463-sec-0072">Appendix 1</a>. </p> </li> <li> <p>MEDLINE Ovid (1946 to 24 September 2021). See <a href="./appendices#CD014463-sec-0073">Appendix 2</a>. </p> </li> <li> <p>Embase Ovid (1947 to 24 September 2021). See <a href="./appendices#CD014463-sec-0074">Appendix 3</a>. </p> </li> <li> <p>The WHO International Clinical Trials Registry Platform (ICTRP) search portal (<a href="http://apps.who.int/trialsearch/Default.aspx" target="_blank">http://apps.who.int/trialsearch/Default.aspx</a>) for all prospectively registered and ongoing studies. See <a href="./appendices#CD014463-sec-0075">Appendix 4</a>. </p> </li> <li> <p>Clinicaltrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">http://clinicaltrials.gov/</a>). See <a href="./appendices#CD014463-sec-0078">Appendix 5</a>. </p> </li> </ul> </p> </section> <section id="CD014463-sec-0025"> <h4 class="title">Searching other resources</h4> <section id="CD014463-sec-0026"> <h5 class="title">Bibliographic searching</h5> <p>We reviewed the reference lists of the included studies or reviews identified through the search. </p> </section> </section> </section> <section id="CD014463-sec-0027"> <h3 class="title" id="CD014463-sec-0027">Data collection and analysis</h3> <section id="CD014463-sec-0028"> <h4 class="title">Selection of studies</h4> <p>Two review authors (RV and MC) looked over the studies identified from the search strategy independently. Each review author applied the selection criteria to identify relevant studies for inclusion. If the review authors disagreed, they reached a consensus through deliberation with the help of a third review author (SSR). We used the PRISMA flow diagram (<a href="./references#CD014463-bbs2-0058" title="PageMJ , McKenzieJE , BossuytPM , BoutronI , HoffmanTC , Mulrow CD et al. The PRISMA 2020 sttatement: an updated guideline for reporting systematic reviews.. BMJ2021;372:n71.">Page 2021</a>) to describe the selection process and recorded all excluded studies in the characteristics of the excluded studies table (<a href="#CD014463-fig-0001">Figure 1</a>). We did not apply any restrictions regarding the language or publication date of the studies. </p> <div class="figure" id="CD014463-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow diagram" data-id="CD014463-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014463.pub2/media/CDSR/CD014463/image_n/nCD014463-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram</p> </div> </div> </div> </section> <section id="CD014463-sec-0029"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (RV and MC) extracted the data, and they resolved any disagreements through discussion with JB and SSR. We collected available data on demographics (age), tumour characteristics (tumour size, grade and receptor status), adjuvant treatments and outcome measures. We performed pooled statistical analysis on outcome measures when there were sufficient data available from the included studies. </p> <p>We entered data into <a href="./references#CD014463-bbs2-0064" title="Review Manager Web (RevMan Web). Version 1.22. The Cochrane Collaboration, 2020. Available from revman.cochrane.org.">RevMan Web</a> for analysis. We requested further information from the corresponding study authors as required about the statistical methods, analysis and results. In circumstances where corresponding study authors did not provide the data that we requested, we have attempted to extract the necessary information from the published results using well‐established statistical methods (<a href="./references#CD014463-bbs2-0073" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8:16.">Tierney 2007</a>). </p> </section> <section id="CD014463-sec-0030"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (RV and MC) assessed the risk of bias independently for each of the included studies, and they resolved any disagreement by discussion with the corresponding review author (SSR). We used Cochrane's risk of bias tool (RoB 1; <a href="./references#CD014463-bbs2-0047" title="HigginsJPT , AltmanDG , Sterne JAC (editors). Chapter 8: assessing risk of bias in included studies. In: HigginsJPT , GreenS , editors(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.">Higgins 2011</a>). This tool involves seven domains to address the quality of randomisation and the degree of bias arising in an RCT. Each domain was divided into three categories ‐ 'low', 'unclear' or 'high' risk ‐ on the basis of specific criteria described in the tool. These judgements enabled us to categorise studies on the basis of their risk of bias and to perform sensitivity analysis when required to assess the effect of the quality of the included studies on the results. </p> </section> <section id="CD014463-sec-0031"> <h4 class="title">Measures of treatment effect</h4> <p>We reported on time‐to‐event outcome measures (i.e. local and regional recurrence, overall survival and disease‐free survival) as hazard ratios (HRs) with 95% confidence intervals (CIs). We extracted the data indirectly from reported results (e.g. log‐rank P values) or Kaplan‐Meier survival curves (<a href="./references#CD014463-bbs2-0060" title="ParmarMKB , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815-34.">Parmar 1998</a>; <a href="./references#CD014463-bbs2-0073" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8:16.">Tierney 2007</a>) when the HR and associated variance were not reported in the published literature. </p> <p>We reported dichotomous outcomes as risk ratios (RRs) with 95% CIs. RR values less than 1 indicate that PMRT is the better treatment option, while RR values greater than 1 indicate that no radiotherapy after mastectomy is better for women with breast cancer and low‐volume axillary disease. </p> <p>For future review versions, if continuous outcome measures (i.e. quality of life) are reported, we will use the standardised mean difference and 95% CI where different scales are used to measure quality of life across studies. If similar scales are used to measure quality of life, we will report the mean difference. </p> </section> <section id="CD014463-sec-0032"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was each individual woman diagnosed with breast cancer. Since we were comparing the effect of PMRT against no radiotherapy in low‐volume axillary disease, we did not consider cross‐over studies and multiple intervention groups. Multiple events per woman were considered only when the second event was a different outcome measure (i.e. if a person develops local and regional recurrence as the first event and then dies due to breast cancer or any other cause (disease‐free survival or overall survival)). </p> </section> <section id="CD014463-sec-0033"> <h4 class="title">Dealing with missing data</h4> <p>There was minimal attrition bias among the included studies in this review. All the studies identified as being eligible for inclusion were subgroup analyses of original RCTs performed to address the effectiveness of PMRT in women diagnosed with breast cancer. </p> </section> <section id="CD014463-sec-0034"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used Cochran's Q test and the I<sup>2</sup> statistic for assessing statistical heterogeneity (<a href="./references#CD014463-bbs2-0030" title="CochranWG . The combination of estimates from different experiments. Biometrics1954;10(1):101-29.">Cochran 1954</a>; <a href="./references#CD014463-bbs2-0046" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327:557-60.">Higgins 2003</a>). For the I<sup>2</sup> statistic, a value of 25% to 50% may represent mild statistical heterogeneity, 50% to 75% may represent moderate statistical heterogeneity, and &gt; 75% may represent considerable statistical heterogeneity (<a href="./references#CD014463-bbs2-0031" title="DeeksJJ , HigginsJPT , AltmanDG , Cochrane Statistical Methods Group. Chapter 10: analysing data and undertaking meta-analyses. In: HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editors(s). Cochrane Database of Systematic Reviews. Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Deeks 2022</a>). We used a random‐effects model for analysis when there was clinical heterogeneity (i.e. variation in women, interventions or outcomes) or methodological heterogeneity (i.e. variation in study design, outcome measurement or risk of bias) in the included studies. </p> </section> <section id="CD014463-sec-0035"> <h4 class="title">Assessment of reporting biases</h4> <p>We could not assess for publication bias using a funnel plot because we included fewer than 10 eligible studies in the review as recommended by the <i>Cochrane Handbook of Systematic Reviews of Interventions</i> (<a href="./references#CD014463-bbs2-0059" title="PageMJ , HigginsJPT , SterneJAC . Chapter 13: assessing risk of bias due to missing results in a synthesis. In: HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editors(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Page 2022</a>). </p> </section> <section id="CD014463-sec-0036"> <h4 class="title">Data synthesis</h4> <p>We performed data synthesis and statistical analysis in <a href="./references#CD014463-bbs2-0064" title="Review Manager Web (RevMan Web). Version 1.22. The Cochrane Collaboration, 2020. Available from revman.cochrane.org.">RevMan Web</a> software. We used random‐effects models that employ the DerSimonian and Laird method (<a href="./references#CD014463-bbs2-0032" title="DerSimonianR , LairdN . Meta-analysis in clinical trials. Controlled Clinical Trials1986;7(3):177-88.">DerSimonian 1986</a>), as the I<sup>2</sup> statistic showed moderate to substantial statistical heterogeneity. Some of the outcome measures were represented narratively due to the lack of sufficient studies to pool the results or when it was not reported in any of the included studies. </p> </section> <section id="CD014463-sec-0037"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We failed to identify any studies investigating the role of age, type of axillary surgery (SLNB alone versus ALND), oestrogen receptor and human epidermal growth factor‐2 receptor (Her2) status on local and regional recurrence in women with early breast cancer and low‐volume axillary nodal disease treated with or without PMRT. Hence, we did not perform any subgroup analysis within an individual study or across included studies. </p> </section> <section id="CD014463-sec-0038"> <h4 class="title">Sensitivity analysis</h4> <p>We did not perform a sensitivity analysis as we only identified three studies, and we describe the outcome from a single study pertaining to modern‐day radiotherapy practice in this review. </p> </section> <section id="CD014463-sec-0039"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>Two review authors (RV and MC) assessed the overall certainty of the evidence by using the GRADE approach (<a href="./references#CD014463-bbs2-0066" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Schünemann 2022</a>). This involved assessing the evidence for each outcome measure using five domains. These domains relate to the risk of bias in the included studies, inconsistency, indirectness, imprecision and publication bias. We created a summary of findings table to address each of these domains for the included studies using <a href="./references#CD014463-bbs2-0042" title="GRADEpro GDT. Version accessed 3 March 2020. Hamilton (ON): McMaster University (developed by Evidence Prime), 2020. Available at gradepro.org.">GRADEpro GDT</a> software for primary and secondary outcome measures. </p> <p>All the included studies in this review were subgroup analyses of the original randomised cohort of women diagnosed with breast cancer and treated with PMRT. Hence none of the included studies was statistically powered to determine the desired or reported outcome measures. Moreover, the type and duration of adjuvant systemic treatments used in the studies included in this review were suboptimal compared to the current standard of care. </p> <p>The study authors of the South Sweden Breast Cancer Group (SSBCG) studies have acknowledged that a lack of a primary hypothesis with no distinction between primary and secondary outcome measures could have resulted in a sample size calculation that was inadequate (<a href="./references#CD014463-bbs2-0002" title="KillanderF , AndersonH , RydeS , MollerT , HafstromLO , MalmstromP . Efficient reduction of loco-regional recurrences but no effect on mortality twenty years after postmastectomy radiation in premenopausal women with stage II breast cancer – a randomized trial from the South Sweden Breast Cancer Group. Breast2009;18:309-15. ">Killander 2009</a>). This was compounded by the fact that they failed to accrue enough women (150 women in each of the three arms of the study) as per the proposed sample size calculation (<a href="./references#CD014463-bbs2-0002" title="KillanderF , AndersonH , RydeS , MollerT , HafstromLO , MalmstromP . Efficient reduction of loco-regional recurrences but no effect on mortality twenty years after postmastectomy radiation in premenopausal women with stage II breast cancer – a randomized trial from the South Sweden Breast Cancer Group. Breast2009;18:309-15. ">Killander 2009</a>). In both studies, there was a gap of 3 weeks between the first 12 doses of radiotherapy and the last 8 doses. This is not a standard practice in the modern‐day administration of radiotherapy following mastectomy. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD014463-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD014463-sec-0040"></div> <section id="CD014463-sec-0041"> <h3 class="title">Description of studies</h3> <section id="CD014463-sec-0042"> <h4 class="title">Results of the search</h4> <p>We retrieved 5328 records from medical databases (CENTRAL, Medline, Embase and CBCG's Specialised Register) and 354 records from clinical study registries (ClinicalTrials.gov and WHO ICTRP). After the removal of duplicate records, we screened 5461 records. Since the review was specifically looking at RCTs, we used the RCT classifier to help distinguish between RCTs (3400 records; high‐probability group) and non‐RCTs (1928 records; low‐probability group). Two review authors (RV and MC) screened the high‐probability group for eligible studies and achieved consensus through discussion with the third review author (SSR). One review author (SSR) screened the low‐probability group and discussed any uncertainties with a second review author (RV). We identified 25 records for full‐text or further review from the high‐probability group and none from the low‐probability group. We selected three studies to be included and one ongoing study for the review and excluded 21 studies with the reasons described in the PRISMA flow chart and <a href="./references#CD014463-sec-0090" title="">Characteristics of excluded studies</a>. See <a href="#CD014463-fig-0001">Figure 1</a>. </p> </section> <section id="CD014463-sec-0043"> <h4 class="title">Included studies</h4> <p>Three studies that fulfilled the eligibility criteria for this review originated from two of the largest randomised studies undertaken in the early 1980s to address the role of PMRT in adjuvant settings (<a href="./references#CD014463-bbs2-0001" title="KillanderF , AndersonH , RydenS , MollerT , AspegrenK , CebergJ , et al. Radiotherapy and tamoxifen after mastectomy in postmenopausal women – 20 year follow-up of the South Sweden Breast Cancer group randomised trial SSBCG II:I. European Journal of Cancer2007;43:2100-8. ">Killander 2007</a>; <a href="./references#CD014463-bbs2-0002" title="KillanderF , AndersonH , RydeS , MollerT , HafstromLO , MalmstromP . Efficient reduction of loco-regional recurrences but no effect on mortality twenty years after postmastectomy radiation in premenopausal women with stage II breast cancer – a randomized trial from the South Sweden Breast Cancer Group. Breast2009;18:309-15. ">Killander 2009</a>; <a href="./references#CD014463-bbs2-0003" title="OvergaardM , NielsenaHM , OvergaardJ . Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&amp;c randomized trials. Radiotherapy and Oncology2007;82:247-53. ">Overgaard 2007</a>). Of these three studies, one study used radiotherapy techniques that are directly comparable to modern‐day practice (<a href="./references#CD014463-bbs2-0003" title="OvergaardM , NielsenaHM , OvergaardJ . Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&amp;c randomized trials. Radiotherapy and Oncology2007;82:247-53. ">Overgaard 2007</a>). </p> <p><a href="./references#CD014463-bbs2-0003" title="OvergaardM , NielsenaHM , OvergaardJ . Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&amp;c randomized trials. Radiotherapy and Oncology2007;82:247-53. ">Overgaard 2007</a> was a subgroup analysis undertaken from the original Danish Breast Cancer Cooperative Group (DBCG) studies investigating the role of PMRT in addition to adjuvant systemic therapy in premenopausal (DBCG 82b: <a href="./references#CD014463-bbs2-0055" title="OvergaardM , HansenPS , OvergaardJ , RoseC , AnderssonM , BachF , et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. New England Journal of Medicine1997;337(14):949-55.">Overgaard 1997</a>) and postmenopausal (DBCG 82c: <a href="./references#CD014463-bbs2-0056" title="OvergaardM , JensenMB , OvergaardJ , HansenPS , RoseC , AnderssonM , et al. Postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 199;353(9165):1641-8. [DOI: 10.1016/S0140-6736(98)09201-0.]">Overgaard 1999</a>) women diagnosed with breast cancer. The subgroup analysis involved only those randomised women with eight or more lymph nodes removed during axillary node clearance and then found to have one to three lymph nodes involved with breast cancer (<a href="./references#CD014463-bbs2-0003" title="OvergaardM , NielsenaHM , OvergaardJ . Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&amp;c randomized trials. Radiotherapy and Oncology2007;82:247-53. ">Overgaard 2007</a>). Participants were randomised to PMRT (n = 256) or no PMRT (n = 256) after total mastectomy and removal of level 1 and partly level 2 axillary lymph nodes. The radiotherapy was administered using a linear accelerator with a target volume of 50 Gy in 25 fractions over 35 days or 48 Gy in 22 fractions over 38 days. Systemic adjuvant therapy was offered based on the menopausal status. All the premenopausal and menopausal women received eight to nine cycles of cyclophosphamide, methotrexate and 5‐fluorouracil (CMF regimen) intravenously every four weeks for nine months. Whereas, postmenopausal women received oral tamoxifen 30 mg daily for 48 weeks. The outcome measures reported in this study included both the locoregional recurrence and overall survival. </p> <p>In their randomised study, the SSBCG published their outcome separately for premenopausal women (<a href="./references#CD014463-bbs2-0002" title="KillanderF , AndersonH , RydeS , MollerT , HafstromLO , MalmstromP . Efficient reduction of loco-regional recurrences but no effect on mortality twenty years after postmastectomy radiation in premenopausal women with stage II breast cancer – a randomized trial from the South Sweden Breast Cancer Group. Breast2009;18:309-15. ">Killander 2009</a>) and postmenopausal women (<a href="./references#CD014463-bbs2-0001" title="KillanderF , AndersonH , RydenS , MollerT , AspegrenK , CebergJ , et al. Radiotherapy and tamoxifen after mastectomy in postmenopausal women – 20 year follow-up of the South Sweden Breast Cancer group randomised trial SSBCG II:I. European Journal of Cancer2007;43:2100-8. ">Killander 2007</a>). The data specific to women diagnosed with breast cancer and found to have one to three involved lymph nodes were available in both the above studies published by the SSBCG. In <a href="./references#CD014463-bbs2-0002" title="KillanderF , AndersonH , RydeS , MollerT , HafstromLO , MalmstromP . Efficient reduction of loco-regional recurrences but no effect on mortality twenty years after postmastectomy radiation in premenopausal women with stage II breast cancer – a randomized trial from the South Sweden Breast Cancer Group. Breast2009;18:309-15. ">Killander 2009</a> and <a href="./references#CD014463-bbs2-0001" title="KillanderF , AndersonH , RydenS , MollerT , AspegrenK , CebergJ , et al. Radiotherapy and tamoxifen after mastectomy in postmenopausal women – 20 year follow-up of the South Sweden Breast Cancer group randomised trial SSBCG II:I. European Journal of Cancer2007;43:2100-8. ">Killander 2007</a>, either premenopausal or postmenopausal women diagnosed with breast cancer and treated with modified radical mastectomy and axillary node clearance were randomised. The randomisation was stratified to the department, tumour size and the number of positive axillary lymph nodes. The study participants were randomised in a 1:1:1 fashion to receive radiotherapy alone, radiotherapy with adjuvant systemic treatment (PMRT group) and only adjuvant systemic treatment (no‐PMRT group). We did not include the radiotherapy‐alone group in this review as the group did not receive any adjuvant systemic treatment and hence were not comparable to the other two groups (i.e. PMRT and no PMRT). The radiotherapy was administered using an orthovoltage ventral beam or an electron ventral field technique to the chest wall with megavoltage photons to the lymph node regions. There was a three‐week gap between the first 12 doses of radiotherapy and the last 8 doses. The maximum targeted skin dose of 45 Gy was administered in 20 fractions over a period of 5 weeks. The treatment protocol with a three‐week gap to diminish skin reactions on the chest wall resulted in a large reduction in the total effective treatment dose. <a href="./references#CD014463-bbs2-0043" title="HavilnadJS , BentzenSM , BlissJM , YarnoldJR . Prolongation of overall treatment time as a cause of treatment failure in early breast cancer: an analysis of the UK START (Standardisation of Breast Radiotherapy) trials of radiotherapy fractionation. Radiotherapy and Oncology2016;121:420-3. [PMID: 27666929]">Haviland 2016</a> estimated that in breast cancer 0.6 Gy per day may be lost in the gap when using regimens of 2 Gy per fraction. The 1.9 Gy per fraction used in this protocol is very close to 2 Gy, and therefore it is estimated that as much as 12.6 Gy of dose could be lost in a three‐week gap during treatment. </p> <p><a href="./references#CD014463-bbs2-0001" title="KillanderF , AndersonH , RydenS , MollerT , AspegrenK , CebergJ , et al. Radiotherapy and tamoxifen after mastectomy in postmenopausal women – 20 year follow-up of the South Sweden Breast Cancer group randomised trial SSBCG II:I. European Journal of Cancer2007;43:2100-8. ">Killander 2007</a> (postmenopausal group) involved women randomised to receive PMRT (n = 79) and no PMRT (n = 94). Both groups were given tamoxifen (30 mg/day) for one year as adjuvant treatment. They reported on local and regional recurrence, time to systemic disease (a surrogate marker for disease‐free survival) and overall mortality without any distinction between primary and secondary outcome measures. </p> <p><a href="./references#CD014463-bbs2-0002" title="KillanderF , AndersonH , RydeS , MollerT , HafstromLO , MalmstromP . Efficient reduction of loco-regional recurrences but no effect on mortality twenty years after postmastectomy radiation in premenopausal women with stage II breast cancer – a randomized trial from the South Sweden Breast Cancer Group. Breast2009;18:309-15. ">Killander 2009</a> (premenopausal group) involved women randomised to receive PMRT (n = 54) or no PMRT (n = 50). Both groups were given 12 cycles of oral cyclophosphamide as adjuvant chemotherapy every 4 weeks. The outcome measures considered were local and regional recurrence with the occurrence of systemic disease and death being competing events, time to systemic disease (a surrogate marker for disease‐free survival) with the occurrence of non‐breast cancer death as a competing event and overall mortality. The results were described using cumulative incidence and mortality curves. There was insufficient information provided to extract the HR for the outcome measures using the methods described by Tierney et al (<a href="./references#CD014463-bbs2-0073" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8:16.">Tierney 2007</a>) in this study. As per <a href="./references#CD014463-bbs2-0001" title="KillanderF , AndersonH , RydenS , MollerT , AspegrenK , CebergJ , et al. Radiotherapy and tamoxifen after mastectomy in postmenopausal women – 20 year follow-up of the South Sweden Breast Cancer group randomised trial SSBCG II:I. European Journal of Cancer2007;43:2100-8. ">Killander 2007</a>, there was no distinction between primary and secondary outcome measures in this study. </p> <section id="CD014463-sec-0044"> <h5 class="title">Ongoing studies</h5> <p>We identified one ongoing study in follow‐up phase, and the results are expected in early 2024 (SUPREMO Trial ‐ <a href="./references#CD014463-bbs2-0025" title="VelikovaG , WilliamsLJ , WillisS , DixonJM , KunklerIH , RussellNS , et al. Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. Lancet Oncology2018;19(11):1516-29. ">Velikova 2018</a>). The SUPREMO study is an open‐label, parallel‐group RCT that has finished recruiting but is in the active phase of follow‐up. Eligible participants were women aged 18 years or older undergoing mastectomy for unilateral intermediate‐risk breast cancer. The intermediate risk was defined as those women with a tumour size less than 5 cm and one to three involved lymph nodes as well as those that are node‐negative with tumour size more than 2 cm but does not involve the skin or underlying muscle. There was only a single study that specifically addressed the quality of life outcome after PMRT (<a href="./references#CD014463-bbs2-0025" title="VelikovaG , WilliamsLJ , WillisS , DixonJM , KunklerIH , RussellNS , et al. Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. Lancet Oncology2018;19(11):1516-29. ">Velikova 2018</a>). </p> <p>The SUPREMO quality of life substudy was preplanned and aimed to examine the effect of PMRT on several quality of life outcome measures at 1, 2, 5 and 10 years only from women recruited in the UK. They published their preliminary results of the quality of life outcome after two years of follow‐up (<a href="./references#CD014463-bbs2-0025" title="VelikovaG , WilliamsLJ , WillisS , DixonJM , KunklerIH , RussellNS , et al. Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. Lancet Oncology2018;19(11):1516-29. ">Velikova 2018</a>). However, the published results included all participants randomised, including women with no involved lymph nodes after axillary staging surgery (N0 disease). Since the study is still ongoing, the study authors were unable to release the data specific to women with one to three involved lymph nodes (N1 disease). </p> </section> </section> <section id="CD014463-sec-0045"> <h4 class="title">Excluded studies</h4> <p>We excluded 21 studies after full‐text review (<a href="./references#CD014463-bbs2-0004" title="ArriagadaR , Rutqvist LE , MattssonA , KramarA , RotsteinS . Adequate locoregional treatment for early breast cancer may prevent secondary dissemination. Journal of Clinical Oncology1995;13(12):2869-78. ">Arriagada 1995</a>; <a href="./references#CD014463-bbs2-0005" title="BaumM , HaybittleJL , BerstockDA . Cancer research campaign (King's/Cambridge) trial for early breast cancer. A detailed update at the 10th year. Lancet1980;2(8185):55-60. ">Baum 1980</a>; <a href="./references#CD014463-bbs2-0006" title="CahlonO , MacDonaldS . Increased cardio and cerebrovascular mortality in breast cancer patients treated with postmastectomy radiotherapy - 25 year follow-up of a randomised trial from the South Sweden Breast Cancer Group: Killander F, Anderson H, Kjellen E, et al (Skane Univ Hosp, Lund, Sweden; Lund Univ, Sweden) Eur J Cancer 50:2201-2210, 2014. Breast Diseases2015;26(1):74-6. ">Cahlon 2015</a>; <a href="./references#CD014463-bbs2-0007" title="FriedlW , ScheurlenHR , HenningsenB . The value of radiotherapy after modified radical mastectomy. 10 year results of the Heidelberg Study. Deutsche Medizinische Wochenschrift1983;108(9):325-30. ">Friedl 1983</a>; <a href="./references#CD014463-bbs2-0008" title="GustavssonA , BendahlPO , CwikielM , EskilssonJ , ThapperKL , PahlmO . No serious late cardiac effects after adjuvant radiotherapy following mastectomy in premenopausal women with early breast cancer. International Journal of Radiation Oncology, Biology, Physics1999;43(4):745-54. ">Gustavsson 1999</a>; <a href="./references#CD014463-bbs2-0010" title="HøjrisI , OvergaardM , ChristensenJJ , OvergaardJ . Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group. Lancet (London, England)1999;354(9188):1425-30. ">Højris 1999</a>; <a href="./references#CD014463-bbs2-0011" title="HøjrisI , AndersenJ , OvergaardM , OvergaardJ . Late treatment-related morbidity in breast cancer patients randomized to postmastectomy radiotherapy and systemic treatment versus systemic treatment alone. Acta Oncologica2000;39(3):355-72. ">Højris 2000</a>; <a href="./references#CD014463-bbs2-0009" title="HoughtonJ , BaumM , HaybittleJL . Role of radiotherapy following total mastectomy in patients with early breast cancer. The Closed Trials Working Party of the CRC Breast Cancer Trials Group. World Journal of Surgery1994;18(1):117-22. ">Houghton 1994</a>; <a href="./references#CD014463-bbs2-0012" title="KillanderF , AndersonH , KjellenE , MalmstromP . Increased cardio and cerebrovascular mortality in breast cancer patients treated with postmastectomy radiotherapy--25 year follow-up of a randomised trial from the South Sweden Breast Cancer Group. European Journal of Cancer2014;50(13):2201-10. ">Killander 2014</a>; <a href="./references#CD014463-bbs2-0013" title="MorganDA , BerridgeJ , BlameyRW . Postoperative radiotherapy following mastectomy for high-risk breast cancer. A randomised trial. European Journal of Cancer2002;38(8):1107-10. ">Morgan 2002</a>; <a href="./references#CD014463-bbs2-0014" title="NielsenHM , OvergaardM , GrauC , JensenAR , OvergaardJ . Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. Journal of Clinical Oncology2006;24(15):2268-75. ">Nielsen 2006</a>; <a href="./references#CD014463-bbs2-0015" title="OsmanMAM , ElkadyMS , NasrKE . For stage II node-positive breast cancer, is it worthwhile to consider adjuvant radiotherapy following mastectomy?Frontiers in Oncology2014;4:1-8. ">Osman 2014</a>; <a href="./references#CD014463-bbs2-0016" title="OvergaardM , Melgaard NielsenH , TrammT , HojrisI , GrantzauT , et al. Postmastectomy RT in high-risk breast cancer. A 30-year update of the DBCG 82bc randomized trial. Radiotherapy and Oncology2020;152:S171. ">Overgaard 2020</a>; <a href="./references#CD014463-bbs2-0017" title="RagazJ , OlivottoIA , SpinelliJJ , PhillipsN , JacksonSM , WilsonKS , et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. Journal of the National Cancer Institute2005;97(2):116-26. ">Ragaz 2005</a>; <a href="./references#CD014463-bbs2-0018" title="RutqvistLE , CedermarkB , GlasU , JohanssonH , RotsteinS , SkoogL , et al. Randomized trial of adjuvant tamoxifen combined with postoperative radiation therapy or adjuvant chemotherapy in postmenopausal breast cancer. Cancer1990;66(1):89-96. ">Rutqvist 1990</a>; <a href="./references#CD014463-bbs2-0019" title="RutqvistLE , LaxI , FornanderT , JohanssonH . Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer. International Journal of Radiation Oncology, Biology, Physics1992;22(5):887-96. ">Rutqvist 1992</a>; <a href="./references#CD014463-bbs2-0020" title="RutqvistLE , JohanssonH . Long-term follow-up of the Stockholm randomized trials of postoperative radiation therapy versus adjuvant chemotherapy among 'high risk' pre- and postmenopausal breast cancer patients. Acta Oncologica2006;45(5):517-27. ">Rutqvist 2006</a>; <a href="./references#CD014463-bbs2-0021" title="SchmoorC , BastertG , DunstJ , BojarH , ChristmannD , UnbehaunV , et al. Randomized trial on the effect of radiotherapy in addition to 6 cycles CMF in node-positive breast-cancer patients. The German Breast-Cancer Study Group. International Journal of Cancer2000;86(3):408-15. ">Schmoor 2000</a>; <a href="./references#CD014463-bbs2-0022" title="SeegenschmiedtMH . Long-term cardiac sequelae of adjuvant radiotherapy after mastectomy? Analysis of Danish DBCG-82b/82c trials. Strahlentherapie und Onkologie2000;176(4):197‐8. ">Seegenschmiedt 2000</a>; <a href="./references#CD014463-bbs2-0023" title="ShiM , LingR , XiaY , LuoS , FuX , XiaoF , et al. Adjuvant chemotherapy and radiotherapy in triple-negative breast carcinoma: a prospective randomized controlled multi-center trial. Radiotherapy and Oncology2011;100(2):200-4. ">Shi 2011</a>; <a href="./references#CD014463-bbs2-0024" title="SmithL , MortimerJE . Randomized trial of post-mastectomy radiotherapy in stage II breast cancer in women with one to three positive axillary nodes, phase III. ClinicalTrials.gov2001. ">Smith 2001</a>). The reasons for exclusions are detailed in the <a href="./references#CD014463-sec-0090" title="">Characteristics of excluded studies</a> tables. </p> </section> </section> <section id="CD014463-sec-0046"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD014463-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD014463-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary for the included studies" data-id="CD014463-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014463.pub2/media/CDSR/CD014463/image_n/nCD014463-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary for the included studies</p> </div> </div> </div> <section id="CD014463-sec-0047"> <h4 class="title">Allocation</h4> <p>Two studies used adequate methods to generate a random sequence and centralised stratified randomisation process (<a href="./references#CD014463-bbs2-0001" title="KillanderF , AndersonH , RydenS , MollerT , AspegrenK , CebergJ , et al. Radiotherapy and tamoxifen after mastectomy in postmenopausal women – 20 year follow-up of the South Sweden Breast Cancer group randomised trial SSBCG II:I. European Journal of Cancer2007;43:2100-8. ">Killander 2007</a>; <a href="./references#CD014463-bbs2-0002" title="KillanderF , AndersonH , RydeS , MollerT , HafstromLO , MalmstromP . Efficient reduction of loco-regional recurrences but no effect on mortality twenty years after postmastectomy radiation in premenopausal women with stage II breast cancer – a randomized trial from the South Sweden Breast Cancer Group. Breast2009;18:309-15. ">Killander 2009</a>) and were judged as low risk of bias. </p> <p>One study (<a href="./references#CD014463-bbs2-0003" title="OvergaardM , NielsenaHM , OvergaardJ . Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&amp;c randomized trials. Radiotherapy and Oncology2007;82:247-53. ">Overgaard 2007</a>), which was a subgroup analysis of randomised women with one to three lymph nodes, selected only those women with eight or more lymph nodes removed during the axillary node clearance. This was done to increase the internal and external validity of the subgroup study as the original randomised cohort of the DBCG 82b (<a href="./references#CD014463-bbs2-0055" title="OvergaardM , HansenPS , OvergaardJ , RoseC , AnderssonM , BachF , et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. New England Journal of Medicine1997;337(14):949-55.">Overgaard 1997</a>) and 82c (<a href="./references#CD014463-bbs2-0056" title="OvergaardM , JensenMB , OvergaardJ , HansenPS , RoseC , AnderssonM , et al. Postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 199;353(9165):1641-8. [DOI: 10.1016/S0140-6736(98)09201-0.]">Overgaard 1999</a>) studies had only a median of seven lymph nodes removed during the axillary nodal clearance. The study authors have not clearly stated how many randomised women with one to three lymph nodes were excluded in this subgroup analysis, thereby introducing selection bias. Thus the study was assessed as having an inadequate randomisation method and judged as high risk of bias in this domain. The same study did use closed‐envelope randomisation at each of the recruiting departments (<a href="./references#CD014463-bbs2-0003" title="OvergaardM , NielsenaHM , OvergaardJ . Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&amp;c randomized trials. Radiotherapy and Oncology2007;82:247-53. ">Overgaard 2007</a>) and was assessed as having adequate allocation concealment. </p> </section> <section id="CD014463-sec-0048"> <h4 class="title">Blinding</h4> <p>Blinding of neither the women nor those administering the treatment was possible due to the use of radiotherapy as the primary intervention. We were not able to identify any description of blinding being considered or attempted in the published manuscript of the included studies. </p> <p>A lack of blinding of women and personnel and when assessing outcomes was not considered to be a serious concern of bias given the objective nature of the outcomes reported. All three studies were deemed at unclear risk of bias for performance and detection bias. </p> </section> <section id="CD014463-sec-0049"> <h4 class="title">Incomplete outcome data</h4> <p>The studies included in this review reported on a subgroup of women identified to have one to three involved lymph nodes amongst the entire randomised cohort. The use of ongoing follow‐up data, revisiting individual hospital records and the national population registry maintained in Denmark and South Sweden ensured near‐complete follow‐up data of the included women. Hence in this review, none of the included studies reported a dropout rate of more than 10%, thus minimising the attrition bias (<a href="./references#CD014463-bbs2-0001" title="KillanderF , AndersonH , RydenS , MollerT , AspegrenK , CebergJ , et al. Radiotherapy and tamoxifen after mastectomy in postmenopausal women – 20 year follow-up of the South Sweden Breast Cancer group randomised trial SSBCG II:I. European Journal of Cancer2007;43:2100-8. ">Killander 2007</a>; <a href="./references#CD014463-bbs2-0002" title="KillanderF , AndersonH , RydeS , MollerT , HafstromLO , MalmstromP . Efficient reduction of loco-regional recurrences but no effect on mortality twenty years after postmastectomy radiation in premenopausal women with stage II breast cancer – a randomized trial from the South Sweden Breast Cancer Group. Breast2009;18:309-15. ">Killander 2009</a>; <a href="./references#CD014463-bbs2-0003" title="OvergaardM , NielsenaHM , OvergaardJ . Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&amp;c randomized trials. Radiotherapy and Oncology2007;82:247-53. ">Overgaard 2007</a>). </p> </section> <section id="CD014463-sec-0050"> <h4 class="title">Selective reporting</h4> <p>The included studies were all registered with the clinical study registries, and all the relevant outcome measures were reported as described in the study protocol. Thus all three studies were deemed at low risk of bias for selective reporting of outcomes. </p> <p>However, it should be emphasised that all the studies were originally recruited to evaluate the role of PMRT in women diagnosed with breast cancer. Hence evaluating the role of PMRT in a subgroup of women with low‐volume axillary disease was unplanned. </p> </section> <section id="CD014463-sec-0051"> <h4 class="title">Other potential sources of bias</h4> <p>In a very small proportion of women (n = 133; 4.3%) in the entire randomised cohort (n = 3078) of the DBCG 82b (<a href="./references#CD014463-bbs2-0055" title="OvergaardM , HansenPS , OvergaardJ , RoseC , AnderssonM , BachF , et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. New England Journal of Medicine1997;337(14):949-55.">Overgaard 1997</a>) and 82c studies (<a href="./references#CD014463-bbs2-0056" title="OvergaardM , JensenMB , OvergaardJ , HansenPS , RoseC , AnderssonM , et al. Postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 199;353(9165):1641-8. [DOI: 10.1016/S0140-6736(98)09201-0.]">Overgaard 1999</a>), orthovoltage radiotherapy was used instead of a linear accelerator to deliver electrons/photons. The lowest intended dose was 36 Gy in 20 fractions given over 4 weeks using the McWhirter technique (<a href="./references#CD014463-bbs2-0056" title="OvergaardM , JensenMB , OvergaardJ , HansenPS , RoseC , AnderssonM , et al. Postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 199;353(9165):1641-8. [DOI: 10.1016/S0140-6736(98)09201-0.]">Overgaard 1999</a>). However, it was not possible to ascertain how many of these women were part of the subgroup analysis of 552 women with one to three positive lymph nodes (<a href="./references#CD014463-bbs2-0003" title="OvergaardM , NielsenaHM , OvergaardJ . Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&amp;c randomized trials. Radiotherapy and Oncology2007;82:247-53. ">Overgaard 2007</a>) relevant to this review. Given the small number of randomised women to whom orthovoltage radiotherapy was given, we did not consider that it would influence the outcome measures considered in this review. </p> <p>In <a href="./references#CD014463-bbs2-0001" title="KillanderF , AndersonH , RydenS , MollerT , AspegrenK , CebergJ , et al. Radiotherapy and tamoxifen after mastectomy in postmenopausal women – 20 year follow-up of the South Sweden Breast Cancer group randomised trial SSBCG II:I. European Journal of Cancer2007;43:2100-8. ">Killander 2007</a> and <a href="./references#CD014463-bbs2-0002" title="KillanderF , AndersonH , RydeS , MollerT , HafstromLO , MalmstromP . Efficient reduction of loco-regional recurrences but no effect on mortality twenty years after postmastectomy radiation in premenopausal women with stage II breast cancer – a randomized trial from the South Sweden Breast Cancer Group. Breast2009;18:309-15. ">Killander 2009</a>, radiotherapy was administered using two different techniques to the chest wall and lymph nodal regions. Moreover, there was a 3‐week gap between the 12thdose and the final 8 doses of radiotherapy. This resulted in a reduction of 12.6 Gy biological equivalent dose delivered to the chest wall and nodal regions. Hence the outcome from both these studies was not pooled for performing a meta‐analysis and has been explained in a descriptive manner. </p> <p>The adjuvant treatment in all the included studies was suboptimal compared to current standard practice. In postmenopausal women, tamoxifen was given (30 mg/day) for one year only (<a href="./references#CD014463-bbs2-0001" title="KillanderF , AndersonH , RydenS , MollerT , AspegrenK , CebergJ , et al. Radiotherapy and tamoxifen after mastectomy in postmenopausal women – 20 year follow-up of the South Sweden Breast Cancer group randomised trial SSBCG II:I. European Journal of Cancer2007;43:2100-8. ">Killander 2007</a>; <a href="./references#CD014463-bbs2-0002" title="KillanderF , AndersonH , RydeS , MollerT , HafstromLO , MalmstromP . Efficient reduction of loco-regional recurrences but no effect on mortality twenty years after postmastectomy radiation in premenopausal women with stage II breast cancer – a randomized trial from the South Sweden Breast Cancer Group. Breast2009;18:309-15. ">Killander 2009</a>; <a href="./references#CD014463-bbs2-0003" title="OvergaardM , NielsenaHM , OvergaardJ . Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&amp;c randomized trials. Radiotherapy and Oncology2007;82:247-53. ">Overgaard 2007</a>) compared to the current standard practice of a minimum of five years of adjuvant endocrine treatment. Moreover, in postmenopausal women, tamoxifen was given as adjuvant systemic treatment irrespective of the oestrogen receptor status (<a href="./references#CD014463-bbs2-0001" title="KillanderF , AndersonH , RydenS , MollerT , AspegrenK , CebergJ , et al. Radiotherapy and tamoxifen after mastectomy in postmenopausal women – 20 year follow-up of the South Sweden Breast Cancer group randomised trial SSBCG II:I. European Journal of Cancer2007;43:2100-8. ">Killander 2007</a>). </p> <p>The use of adjuvant systemic chemotherapy has evolved and is significantly different from the agents used in the included studies. <a href="./references#CD014463-bbs2-0002" title="KillanderF , AndersonH , RydeS , MollerT , HafstromLO , MalmstromP . Efficient reduction of loco-regional recurrences but no effect on mortality twenty years after postmastectomy radiation in premenopausal women with stage II breast cancer – a randomized trial from the South Sweden Breast Cancer Group. Breast2009;18:309-15. ">Killander 2009</a> used 12 courses of oral cyclophosphamide 130 mg/m<sup>2</sup> for 14 days every 4 weeks, while <a href="./references#CD014463-bbs2-0003" title="OvergaardM , NielsenaHM , OvergaardJ . Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&amp;c randomized trials. Radiotherapy and Oncology2007;82:247-53. ">Overgaard 2007</a> used 8 to 9 cycles of CMF (cyclophosphamide 600 mg/m<sup>2</sup>, methotrexate 40 mg/m<sup>2</sup> and 5‐fluorouracil 600 mg/m<sup>2</sup>) intravenously every 4 weeks for 9 months. These differences in practice should be considered while interpreting the results of this review. </p> </section> </section> <section id="CD014463-sec-0052"> <h3 class="title" id="CD014463-sec-0052">Effects of interventions</h3> <p>See: <a href="./full#CD014463-tbl-0001"><b>Summary of findings 1</b> Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) compared to no PMRT in women with breast cancer and one to three positive lymph nodes</a> </p> <section id="CD014463-sec-0053"> <h4 class="title">Local and regional recurrence</h4> <p>The primary outcome measure was described in one study, which used radiotherapy techniques comparable to modern‐day radiotherapy methods (<a href="./references#CD014463-bbs2-0003" title="OvergaardM , NielsenaHM , OvergaardJ . Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&amp;c randomized trials. Radiotherapy and Oncology2007;82:247-53. ">Overgaard 2007</a>). There was a substantial reduction in local and regional recurrence in the PMRT group (HR 0.20, 95% CI 0.13 to 0.33, 522 women; low‐certainty evidence; <a href="./references#CD014463-fig-0003" title="">Analysis 1.1</a>). </p> <p>In the remaining two studies (<a href="./references#CD014463-bbs2-0001" title="KillanderF , AndersonH , RydenS , MollerT , AspegrenK , CebergJ , et al. Radiotherapy and tamoxifen after mastectomy in postmenopausal women – 20 year follow-up of the South Sweden Breast Cancer group randomised trial SSBCG II:I. European Journal of Cancer2007;43:2100-8. ">Killander 2007</a>; <a href="./references#CD014463-bbs2-0002" title="KillanderF , AndersonH , RydeS , MollerT , HafstromLO , MalmstromP . Efficient reduction of loco-regional recurrences but no effect on mortality twenty years after postmastectomy radiation in premenopausal women with stage II breast cancer – a randomized trial from the South Sweden Breast Cancer Group. Breast2009;18:309-15. ">Killander 2009</a>), there was insufficient information provided to extract HRs for local and regional recurrence, and we were unable to obtain the individual data from the study authors. However, cumulative incidence at 20 years, accounting for the competing risks of distant recurrence and death, was reported in both studies. Both studies (<a href="./references#CD014463-bbs2-0001" title="KillanderF , AndersonH , RydenS , MollerT , AspegrenK , CebergJ , et al. Radiotherapy and tamoxifen after mastectomy in postmenopausal women – 20 year follow-up of the South Sweden Breast Cancer group randomised trial SSBCG II:I. European Journal of Cancer2007;43:2100-8. ">Killander 2007</a>; <a href="./references#CD014463-bbs2-0002" title="KillanderF , AndersonH , RydeS , MollerT , HafstromLO , MalmstromP . Efficient reduction of loco-regional recurrences but no effect on mortality twenty years after postmastectomy radiation in premenopausal women with stage II breast cancer – a randomized trial from the South Sweden Breast Cancer Group. Breast2009;18:309-15. ">Killander 2009</a>) reported decreased cumulative incidence of local and regional recurrence at 20 years in the PMRT group compared to the no‐PMRT group. In postmenopausal women, the cumulative incidence of local and regional recurrence was 2.6% (95% CI 0.5 to 8.3, 79 women) in the PMRT group and 25.9% (95% CI 17.5 to 35.1, 94 women) in the no‐PMRT group (<a href="./references#CD014463-bbs2-0001" title="KillanderF , AndersonH , RydenS , MollerT , AspegrenK , CebergJ , et al. Radiotherapy and tamoxifen after mastectomy in postmenopausal women – 20 year follow-up of the South Sweden Breast Cancer group randomised trial SSBCG II:I. European Journal of Cancer2007;43:2100-8. ">Killander 2007</a>). In premenopausal women, the cumulative incidence of local and regional recurrence was 3.9% (95% CI 0.7 to 11.9, 54 women) and 14.8% (95% CI 6.5 to 26.3, 50 women), respectively (<a href="./references#CD014463-bbs2-0002" title="KillanderF , AndersonH , RydeS , MollerT , HafstromLO , MalmstromP . Efficient reduction of loco-regional recurrences but no effect on mortality twenty years after postmastectomy radiation in premenopausal women with stage II breast cancer – a randomized trial from the South Sweden Breast Cancer Group. Breast2009;18:309-15. ">Killander 2009</a>). Even though we were unable to extract the HR from these two studies, there was concordance in the findings, suggesting a reduction in local and regional recurrence amongst the PMRT group compared to the no‐PMRT group. </p> </section> <section id="CD014463-sec-0054"> <h4 class="title">Overall survival</h4> <p>The overall survival was reported in two studies at 15 years (<a href="./references#CD014463-bbs2-0003" title="OvergaardM , NielsenaHM , OvergaardJ . Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&amp;c randomized trials. Radiotherapy and Oncology2007;82:247-53. ">Overgaard 2007</a>) and 25 years (<a href="./references#CD014463-bbs2-0001" title="KillanderF , AndersonH , RydenS , MollerT , AspegrenK , CebergJ , et al. Radiotherapy and tamoxifen after mastectomy in postmenopausal women – 20 year follow-up of the South Sweden Breast Cancer group randomised trial SSBCG II:I. European Journal of Cancer2007;43:2100-8. ">Killander 2007</a>) follow‐up. The one study that used radiotherapy techniques comparable to modern‐day radiotherapy methods reported an improvement in overall survival amongst the PMRT group compared to the no‐PMRT group (HR 0.76, 95% CI 0.60 to 0.97, 552 women; moderate‐certainty evidence; <a href="./references#CD014463-fig-0004" title="">Analysis 1.2</a>; <a href="./references#CD014463-bbs2-0003" title="OvergaardM , NielsenaHM , OvergaardJ . Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&amp;c randomized trials. Radiotherapy and Oncology2007;82:247-53. ">Overgaard 2007</a>). </p> <p>In the other study involving postmenopausal women (<a href="./references#CD014463-bbs2-0001" title="KillanderF , AndersonH , RydenS , MollerT , AspegrenK , CebergJ , et al. Radiotherapy and tamoxifen after mastectomy in postmenopausal women – 20 year follow-up of the South Sweden Breast Cancer group randomised trial SSBCG II:I. European Journal of Cancer2007;43:2100-8. ">Killander 2007</a>), there was little difference in overall survival amongst the PMRT group compared to the no‐PMRT group (HR 0.90, 95% CI 0.66 to 1.20, 173 women). </p> <p>It was not possible to extract HRs for the study involving premenopausal women (<a href="./references#CD014463-bbs2-0002" title="KillanderF , AndersonH , RydeS , MollerT , HafstromLO , MalmstromP . Efficient reduction of loco-regional recurrences but no effect on mortality twenty years after postmastectomy radiation in premenopausal women with stage II breast cancer – a randomized trial from the South Sweden Breast Cancer Group. Breast2009;18:309-15. ">Killander 2009</a>), but overall mortality at 20 years was reported in the PMRT group as 33% (95% CI 25 to 48) compared to the no‐PMRT group at 50% (95% CI 38 to 64) and did not reach statistical significance (P = 0.086). </p> </section> <section id="CD014463-sec-0055"> <h4 class="title">Disease‐free survival</h4> <p>Data for disease‐free survival were not reported by the one study using radiotherapy techniques comparable to modern radiotherapy methods (<a href="./references#CD014463-bbs2-0003" title="OvergaardM , NielsenaHM , OvergaardJ . Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&amp;c randomized trials. Radiotherapy and Oncology2007;82:247-53. ">Overgaard 2007</a>). </p> <p>The remaining studies reported some disease‐free survival data. <a href="./references#CD014463-bbs2-0001" title="KillanderF , AndersonH , RydenS , MollerT , AspegrenK , CebergJ , et al. Radiotherapy and tamoxifen after mastectomy in postmenopausal women – 20 year follow-up of the South Sweden Breast Cancer group randomised trial SSBCG II:I. European Journal of Cancer2007;43:2100-8. ">Killander 2007</a> reported the outcome in a cumulative incidence curve, accounting for the competing risk of non‐breast cancer deaths. Applying the methods described by <a href="./references#CD014463-bbs2-0073" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8:16.">Tierney 2007</a>, a subdistribution HR was extracted comparing the cumulative incidence of disease‐free survival in the PMRT group compared to the no‐PMRT group (<a href="./references#CD014463-bbs2-0037" title="FineJP , GrayRJ . A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association1999;94:496-509.">Fine 1999</a>). The subdistribution HR should be interpreted in the context of a competing risks analysis, where the impact of factors affecting the competing risk on the cumulative incidence of disease‐free survival was taken into account (<a href="./references#CD014463-bbs2-0050" title="McCawZR , ClaggettBL , TianL , SolomonSD , BerwangerO , PfefferMA , et al. Practical recommendations on quantifying and interpreting treatment effects in the presence of terminal competing risks: a review. JAMA Cardiology2022;7(4):450-6.">McCaw 2022</a>). The subdistribution HR extracted from the cumulative incidence curves reported by <a href="./references#CD014463-bbs2-0001" title="KillanderF , AndersonH , RydenS , MollerT , AspegrenK , CebergJ , et al. Radiotherapy and tamoxifen after mastectomy in postmenopausal women – 20 year follow-up of the South Sweden Breast Cancer group randomised trial SSBCG II:I. European Journal of Cancer2007;43:2100-8. ">Killander 2007</a> showed a statistically significant improvement in disease‐free survival amongst the PMRT group (subdistribution HR 0.63, 95% CI 0.41 to 0.96, 173 women; <a href="./references#CD014463-fig-0005" title="">Analysis 1.3</a>). </p> <p><a href="./references#CD014463-bbs2-0002" title="KillanderF , AndersonH , RydeS , MollerT , HafstromLO , MalmstromP . Efficient reduction of loco-regional recurrences but no effect on mortality twenty years after postmastectomy radiation in premenopausal women with stage II breast cancer – a randomized trial from the South Sweden Breast Cancer Group. Breast2009;18:309-15. ">Killander 2009</a> provided the cumulative incidence of disease‐free survival at 20 years in the premenopausal group and reported no difference in the cumulative incidence of systemic disease between the PMRT group (35%; 95% CI 22 to 48) and no‐PMRT group (38%; 95% CI 24 to 51). </p> </section> <section id="CD014463-sec-0056"> <h4 class="title">Time to progression</h4> <p>The studies did not report this outcome for women diagnosed with breast cancer and one to three positive lymph nodes and randomised to have PMRT. </p> </section> <section id="CD014463-sec-0057"> <h4 class="title">Short‐term adverse events</h4> <p>The studies did not report this outcome for women diagnosed with breast cancer and one to three positive lymph nodes and randomised to have PMRT. </p> </section> <section id="CD014463-sec-0058"> <h4 class="title">Long‐term adverse events</h4> <p>The studies did not report this outcome for women diagnosed with breast cancer and one to three positive lymph nodes and randomised to have PMRT. </p> </section> <section id="CD014463-sec-0059"> <h4 class="title">Quality of life</h4> <p>We identified one ongoing study (SUPREMO) that reported on the two‐year quality of life outcome after PMRT (<a href="./references#CD014463-bbs2-0025" title="VelikovaG , WilliamsLJ , WillisS , DixonJM , KunklerIH , RussellNS , et al. Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. Lancet Oncology2018;19(11):1516-29. ">Velikova 2018</a>). However, since the study is in the active follow‐up stage, the study authors could not release the data specific to women diagnosed with one to three involved lymph nodes. Hence, we were unable to report on this important outcome measure in the current review. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD014463-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD014463-sec-0060"></div> <section id="CD014463-sec-0061"> <h3 class="title" id="CD014463-sec-0061">Summary of main results</h3> <p>Three RCTs met the inclusion criteria (<a href="./references#CD014463-bbs2-0001" title="KillanderF , AndersonH , RydenS , MollerT , AspegrenK , CebergJ , et al. Radiotherapy and tamoxifen after mastectomy in postmenopausal women – 20 year follow-up of the South Sweden Breast Cancer group randomised trial SSBCG II:I. European Journal of Cancer2007;43:2100-8. ">Killander 2007</a>; <a href="./references#CD014463-bbs2-0002" title="KillanderF , AndersonH , RydeS , MollerT , HafstromLO , MalmstromP . Efficient reduction of loco-regional recurrences but no effect on mortality twenty years after postmastectomy radiation in premenopausal women with stage II breast cancer – a randomized trial from the South Sweden Breast Cancer Group. Breast2009;18:309-15. ">Killander 2009</a>; <a href="./references#CD014463-bbs2-0003" title="OvergaardM , NielsenaHM , OvergaardJ . Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&amp;c randomized trials. Radiotherapy and Oncology2007;82:247-53. ">Overgaard 2007</a>), with only one study using radiotherapy techniques that are comparable to modern‐day practice (<a href="./references#CD014463-bbs2-0003" title="OvergaardM , NielsenaHM , OvergaardJ . Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&amp;c randomized trials. Radiotherapy and Oncology2007;82:247-53. ">Overgaard 2007</a>). All studies were all subgroup analyses of original RCTs conducted in the 1980s to assess the effectiveness of PMRT in women diagnosed with breast cancer. Hence, the type and duration of adjuvant systemic treatments used in the included studies were suboptimal compared to the current standard of care. </p> <p>The one study that most reflected current radiotherapy practice (<a href="./references#CD014463-bbs2-0003" title="OvergaardM , NielsenaHM , OvergaardJ . Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&amp;c randomized trials. Radiotherapy and Oncology2007;82:247-53. ">Overgaard 2007</a>) reported local and regional recurrence and overall survival. Low‐certainty evidence indicated an improvement in local and regional recurrence. Moderate‐certainty evidence showed an improvement in overall survival amongst the PMRT group compared to the no‐PMRT group. </p> <p>One of the other studies that did not use modern‐day radiotherapy techniques reported disease‐free survival and showed a significantly better 20‐year disease‐free survival in the PMRT group than the no‐PMRT group (<a href="./references#CD014463-bbs2-0001" title="KillanderF , AndersonH , RydenS , MollerT , AspegrenK , CebergJ , et al. Radiotherapy and tamoxifen after mastectomy in postmenopausal women – 20 year follow-up of the South Sweden Breast Cancer group randomised trial SSBCG II:I. European Journal of Cancer2007;43:2100-8. ">Killander 2007</a>). </p> <p>The lack of published evidence meant that we were not able to report on the time to progression, adverse events and quality of life secondary outcomes in this review. A recent study has reported on quality of life outcomes after PMRT (<a href="./references#CD014463-bbs2-0025" title="VelikovaG , WilliamsLJ , WillisS , DixonJM , KunklerIH , RussellNS , et al. Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. Lancet Oncology2018;19(11):1516-29. ">Velikova 2018</a>) as a substudy of the ongoing SUPREMO Trial. However, the study investigators were unable to provide quality of life data specifically for women diagnosed with one to three positive lymph nodes due to the ongoing nature of the SUPREMO Trial. </p> </section> <section id="CD014463-sec-0062"> <h3 class="title" id="CD014463-sec-0062">Overall completeness and applicability of evidence</h3> <p>There is a paucity of data on this topic. The results presented in this review were drawn from 3 RCTs. We were not able to pool the results to perform a meta‐analysis as only one study pertained to the modern‐day radiotherapy technique. The result for the primary endpoint of local and regional recurrence was extracted from a single RCT. We were not able to identify any studies to address the secondary outcome measures related to time to progression, short‐ and long‐term side effects and quality of life after PMRT. </p> <p>The included studies were all subgroup analyses of previously conducted RCTs performed to evaluate the role of PMRT in women diagnosed with breast cancer. Hence, they were not designed specifically to answer the effectiveness of PMRT in women with breast cancer and one to three positive lymph nodes. </p> <p>There is a lack of evidence within the literature on the effectiveness of the current standard‐of‐care radiotherapy techniques in women with breast cancer and low‐volume axillary disease. The radiotherapy in all included studies was suboptimal compared to the current standard practice with modern photon radiotherapy. None of the studies reviewed used megavoltage photons as the primary treatment for the chest wall target area. The use of intensity‐modulated photon radiotherapy, volumetric modulated arc therapy and deep inspiratory breath hold radiotherapy was not standard practice at the time of the included studies in this review. These modern radiotherapy techniques can improve the therapeutic ratio between cancer outcomes and late toxicity. Due to the lack of data on modern radiotherapy techniques in the low‐volume axillary disease group, we limited our inclusion of radiotherapy intervention to those techniques considered acceptable to the current ongoing SUPREMO Trial so that future comparisons could be made and excluded older interventions such as cobalt‐60 radiotherapy. </p> <p>Further consideration should be given while interpreting the results of this review in light of the type of systemic endocrine and chemotherapy medications used in the included studies. The advancement in modern endocrine, chemotherapy and targeted immunotherapy treatments may mitigate or reduce the magnitude of the improvement in overall survival observed with PMRT in this review. </p> <p>There was a lack of published and available data to evaluate the role of dose escalation, uses of chest wall bolus and chest wall boost as part of the PMRT technique in this review. </p> </section> <section id="CD014463-sec-0063"> <h3 class="title" id="CD014463-sec-0063">Quality of the evidence</h3> <p>We identified three RCTs that fulfilled the inclusion criteria involving a total of 829 women (PMRT 409, no PMRT 420). We were unable to extract data from one of the included studies (<a href="./references#CD014463-bbs2-0002" title="KillanderF , AndersonH , RydeS , MollerT , HafstromLO , MalmstromP . Efficient reduction of loco-regional recurrences but no effect on mortality twenty years after postmastectomy radiation in premenopausal women with stage II breast cancer – a randomized trial from the South Sweden Breast Cancer Group. Breast2009;18:309-15. ">Killander 2009</a>) to pool the outcome measures and hence described the findings in a descriptive manner (PMRT 54, no PMRT 50). </p> <p>The internal validity of one of the largest studies (<a href="./references#CD014463-bbs2-0003" title="OvergaardM , NielsenaHM , OvergaardJ . Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&amp;c randomized trials. Radiotherapy and Oncology2007;82:247-53. ">Overgaard 2007</a>) was compromised due to the method used for randomisation and allocation concealment. The studies included in this review were all subgroup analyses of original RCTs conducted in the early 1980s to evaluate the role of PMRT in breast cancer. This allowed the included studies to be comparable and hence reduced statistical heterogeneity. However, the type and duration of various systemic adjuvant treatments being offered to the women randomised in these studies were substantially different in efficacy compared to the modern chemo‐endocrine treatments. There was a very low attrition bias at the expense of compromised power due to the subgroup analysis performed in the included studies. </p> <p>The overall confidence in the primary outcome measure (local and regional recurrence) is low due to the inability to pool the data and the concerns about the quality of the evidence of the only study from which the data were extracted. The estimated effect seen for overall survival is more likely to be closer to the expected true effect. </p> </section> <section id="CD014463-sec-0064"> <h3 class="title" id="CD014463-sec-0064">Potential biases in the review process</h3> <p>Since this was an interventional review, it was essential to include only RCTs to ensure that both PMRT and no‐PMRT groups remain comparable. Even though this minimised selection bias, it resulted in the identification of only three RCTs eligible for inclusion in this review. We wanted to ensure that the type of radiotherapy used in the included studies was comparable to what would be acceptable as close to the current standard practice as possible and therefore accepted techniques that would be included in the ongoing SUPREMO Trial (<a href="./references#CD014463-bbs2-0025" title="VelikovaG , WilliamsLJ , WillisS , DixonJM , KunklerIH , RussellNS , et al. Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. Lancet Oncology2018;19(11):1516-29. ">Velikova 2018</a>). Hence, amongst three eligible RCTs, only a single study pertaining to the modern‐day radiotherapy technique was represented in the main outcome measures to allow us to combine the data once the results of the SUPREMO Trial are published. This also limited the number of studies that could be included in this review compared to some other larger reviews and meta‐analyses that have been published (<a href="./references#CD014463-bbs2-0036" title="Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet2014;383(9935):2127-35.">EBCTCG 2014</a>; <a href="./references#CD014463-bbs2-0049" title="LiY , MoranMS , HuoQ , HafftyBG . Post-mastectomy radiotherapy for breast cancer patients with T1-T2 and 1-3 positive lymph nodes: a meta-analysis. PLoS ONE2013;8(12):e81765.">Li 2013</a>; <a href="./references#CD014463-bbs2-0077" title="WhelanTJ , JulianJ , WrightJ , JadadAR , LevineML . Does locoregional radiation therapy improve survival in breast cancer? A meta- analysis. Journal of Clinical Oncology March 2000;18(6):1220-9.">Whelan 2000</a>). There are very few studies that have reported short‐term side effects after PMRT, and we were unable to identify any studies reporting long‐term side effects. This was potentially due to two factors: lack of side effects reported specifically in the one to three positive lymph node groups and lack of predefined follow‐up of RCTs to ascertain the long‐term side effects. </p> <p>We identified two additional studies that could have been included in this review. However, the lack of information in the published report and the inability to gather information from the study authors meant that it was not possible to ascertain whether these studies were randomised, quasi‐randomised or prospective cohort studies (<a href="./references#CD014463-bbs2-0054" title="OsmanMAM , ElkadyMS , NasrKE . For stage II node positive breast cancer, is it worthwhile to consider adjuvant radiotherapy following mastectomy?Frontiers in Oncology2014;4:1-8. [DOI: 10.3389/fonc.2014.00326]">Osman 2014</a>; <a href="./references#CD014463-bbs2-0068" title="ShiM , LingR , XiaY , LuoS , FuX , XiaoF , et al. Adjuvant chemotherapy and radiotherapy in triple-negative breast carcinoma: a prospective randomized controlled multi-center trial. Radiotherapy and Oncology2011;100(2):200-4.">Shi 2011</a>). We were unable to combine the data for performing a pooled analysis for our primary and secondary outcome measures. This was due to only one out of the three eligible studies using radiotherapy techniques that are comparable to modern‐day methods. There were also different statistical methods used for reporting the secondary outcome measures in the eligible studies for inclusion with some studies reporting insufficient information to extract HRs. Finally, we were unable to obtain any data on the side effects and quality of life outcomes after PMRT. Both of these outcome measures are important in helping to understand the overall effect of PMRT in women with one to three positive lymph nodes. </p> </section> <section id="CD014463-sec-0065"> <h3 class="title" id="CD014463-sec-0065">Agreements and disagreements with other studies or reviews</h3> <p>There are four published meta‐analyses evaluating the role of PMRT in women with one to three positive lymph nodes (<a href="./references#CD014463-bbs2-0036" title="Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet2014;383(9935):2127-35.">EBCTCG 2014</a>; <a href="./references#CD014463-bbs2-0044" title="HeadonH , KasemA , AlmukbelR , MokbelK . Improvement of survival with postmastectomy radiotherapy in patients with 1-3 positive axillary nodes: a systematic review and meta analysis of the current literature. Molecular and Clinical Oncology2016;5:429-36.">Headon 2016</a>; <a href="./references#CD014463-bbs2-0049" title="LiY , MoranMS , HuoQ , HafftyBG . Post-mastectomy radiotherapy for breast cancer patients with T1-T2 and 1-3 positive lymph nodes: a meta-analysis. PLoS ONE2013;8(12):e81765.">Li 2013</a>; <a href="./references#CD014463-bbs2-0077" title="WhelanTJ , JulianJ , WrightJ , JadadAR , LevineML . Does locoregional radiation therapy improve survival in breast cancer? A meta- analysis. Journal of Clinical Oncology March 2000;18(6):1220-9.">Whelan 2000</a>). </p> <p><a href="./references#CD014463-bbs2-0077" title="WhelanTJ , JulianJ , WrightJ , JadadAR , LevineML . Does locoregional radiation therapy improve survival in breast cancer? A meta- analysis. Journal of Clinical Oncology March 2000;18(6):1220-9.">Whelan 2000</a> presented one of the earliest meta‐analyses evaluating the role of PMRT and included 18 randomised studies between 1967 and 1999, involving 6367 women diagnosed with breast cancer. They included all studies in which PMRT was administered irrespective of the axillary lymph nodal status. In spite of this, they were able to demonstrate an overall survival benefit for women undergoing PMRT. <a href="./references#CD014463-bbs2-0049" title="LiY , MoranMS , HuoQ , HafftyBG . Post-mastectomy radiotherapy for breast cancer patients with T1-T2 and 1-3 positive lymph nodes: a meta-analysis. PLoS ONE2013;8(12):e81765.">Li 2013</a> performed a meta‐analysis of nonrandomised cohort studies reporting on the role of PMRT in one to three positive nodes. They were able to show that there was a substantial improvement in local and regional recurrence with PMRT (degrees of freedom (df) 9, RR 0.348, 95% CI 0.254 to 0.477) from the 10 studies eligible for inclusion. However, the pooled analysis from six eligible studies showed no improvement in overall survival amongst women receiving PMRT. However, it should be noted that most of the women in these studies were treated between 1983 and 2006, resulting in substantial variability in the adjuvant treatments being offered, which would have an effect on the reported outcome measures. </p> <p>The <a href="./references#CD014463-bbs2-0036" title="Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet2014;383(9935):2127-35.">EBCTCG 2014</a> published an exhaustive meta‐analysis of 22 RCTs from 1964 to 1986 evaluating the role of PMRT in women with one to three lymph node‐positive diseases. The meta‐analysis included all the studies included in this review. We excluded the remaining 19 studies due to their use of cobalt‐60 radiotherapy, having a target dose of more than 50Gy and not performing an axillary surgery to adequately stage the breast cancer. We based the permissible radiotherapy techniques in this review on those acceptable to the SUPREMO Trial to enable future comparisons to be made. We also excluded dose escalation (e.g. in the form of chest wall boost dose as there is no standard consensus for this approach). The <a href="./references#CD014463-bbs2-0036" title="Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet2014;383(9935):2127-35.">EBCTCG 2014</a> of 1133 women who received some form of adjuvant systemic treatment (chemotherapy and endocrine) demonstrated that PMRT substantially reduces 10‐year local and regional recurrence (4.3% versus 21%, two‐tailed P &lt; 0.00001) and improves 20‐year breast cancer‐specific mortality (41.5% versus 49.4%, RR 0.78, 95% CI 0.64 to 0.94, two‐tailed P = 0.01). Most of the women had systemic chemotherapy using the CMF regimen, systemic treatments involving ovarian irradiation were administered in two studies and systemic endocrine (tamoxifen) treatment was administered only in three studies. Hence, similar to our results, care should be taken while interpreting the magnitude of these results due to the difference in the effectiveness of the systemic treatment used in the included studies compared to that of the modern chemo‐endocrine agents. </p> <p><a href="./references#CD014463-bbs2-0044" title="HeadonH , KasemA , AlmukbelR , MokbelK . Improvement of survival with postmastectomy radiotherapy in patients with 1-3 positive axillary nodes: a systematic review and meta analysis of the current literature. Molecular and Clinical Oncology2016;5:429-36.">Headon 2016</a> presented a meta‐analysis combining retrospective cohort studies and RCTs evaluating the effect of PMRT in women with one to three positive axillary lymph nodes. The local and regional recurrence analysis included 11 studies, and only 2 of these were RCTs. The remaining 9 were retrospective studies. The two RCTs included in the local and regional recurrence analysis were <a href="./references#CD014463-bbs2-0003" title="OvergaardM , NielsenaHM , OvergaardJ . Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&amp;c randomized trials. Radiotherapy and Oncology2007;82:247-53. ">Overgaard 2007</a> and <a href="./references#CD014463-bbs2-0062" title="RagazJ , OlivottoIA , SpinelliJJ , PhillipsN , JacksonSM , WilsonKS , et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. Journal of the National Cancer Institute2005;97(2):116-26.">Ragaz 2005</a>, with a total weightage of RCTs in the analysis being 59%. There was a statistically significant lower local and regional recurrence amongst PMRT women compared to no PMRT (RR 0.30, 95% CI 0.23 to 0.38). We excluded <a href="./references#CD014463-bbs2-0062" title="RagazJ , OlivottoIA , SpinelliJJ , PhillipsN , JacksonSM , WilsonKS , et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. Journal of the National Cancer Institute2005;97(2):116-26.">Ragaz 2005</a> from our review as they used cobalt‐60 radiotherapy, which is not considered an international standard of care moving forward The overall survival analysis involved only a single RCT (<a href="./references#CD014463-bbs2-0062" title="RagazJ , OlivottoIA , SpinelliJJ , PhillipsN , JacksonSM , WilsonKS , et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. Journal of the National Cancer Institute2005;97(2):116-26.">Ragaz 2005</a>) with a weightage of 3.5% and showed a 3% improvement in overall survival amongst the PMRT group but did not reach statistical significance. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD014463-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/media/CDSR/CD014463/urn:x-wiley:14651858:media:CD014463:CD014463-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram" data-id="CD014463-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014463.pub2/media/CDSR/CD014463/image_n/nCD014463-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/media/CDSR/CD014463/image_t/tCD014463-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/full#CD014463-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/media/CDSR/CD014463/image_n/nCD014463-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014463-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/media/CDSR/CD014463/urn:x-wiley:14651858:media:CD014463:CD014463-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary for the included studies" data-id="CD014463-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014463.pub2/media/CDSR/CD014463/image_n/nCD014463-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/media/CDSR/CD014463/image_t/tCD014463-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary for the included studies</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/full#CD014463-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/media/CDSR/CD014463/image_n/nCD014463-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014463-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/media/CDSR/CD014463/urn:x-wiley:14651858:media:CD014463:CD014463-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PMRT versus no PMRT in women with one to three positive lymph nodes, Outcome 1: Locoregional recurrence (LRR)" data-id="CD014463-fig-0003" src="/cdsr/doi/10.1002/14651858.CD014463.pub2/media/CDSR/CD014463/image_n/nCD014463-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/media/CDSR/CD014463/image_t/tCD014463-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: PMRT versus no PMRT in women with one to three positive lymph nodes, Outcome 1: Locoregional recurrence (LRR) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/references#CD014463-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/media/CDSR/CD014463/image_n/nCD014463-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014463-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/media/CDSR/CD014463/urn:x-wiley:14651858:media:CD014463:CD014463-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PMRT versus no PMRT in women with one to three positive lymph nodes, Outcome 2: Overall survival (OS)" data-id="CD014463-fig-0004" src="/cdsr/doi/10.1002/14651858.CD014463.pub2/media/CDSR/CD014463/image_n/nCD014463-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/media/CDSR/CD014463/image_t/tCD014463-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: PMRT versus no PMRT in women with one to three positive lymph nodes, Outcome 2: Overall survival (OS) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/references#CD014463-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/media/CDSR/CD014463/image_n/nCD014463-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014463-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/media/CDSR/CD014463/urn:x-wiley:14651858:media:CD014463:CD014463-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: PMRT versus no PMRT in women with one to three positive lymph nodes, Outcome 3: Disease‐free survival (DFS)" data-id="CD014463-fig-0005" src="/cdsr/doi/10.1002/14651858.CD014463.pub2/media/CDSR/CD014463/image_n/nCD014463-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/media/CDSR/CD014463/image_t/tCD014463-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: PMRT versus no PMRT in women with one to three positive lymph nodes, Outcome 3: Disease‐free survival (DFS) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/references#CD014463-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/media/CDSR/CD014463/image_n/nCD014463-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD014463-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) compared to no PMRT in women with breast cancer and one to three positive lymph nodes</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Postmastectomy radiotherapy (PMRT) compared to no PMRT in women with breast cancer and one to three positive lymph nodes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women with breast cancer and one to three positive lymph nodes<br/><b>Setting:</b> Postoperative follow‐up<br/><b>Intervention:</b> postmastectomy radiotherapy (PMRT)<br/><b>Comparison:</b> no PMRT </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no PMRT</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with postmastectomy radiotherapy (PMRT)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Local and regional recurrence (LRR)<br/>follow‐up: 15 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>10‐year risk of LRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.20</b><br/>(0.13 to 0.33)<br/>[Local and regional recurrence] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>552<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>255 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b><br/>(38 to 93) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival (OS)<br/>follow‐up: 25 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>10‐year risk of death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.76</b><br/>(0.60 to 0.97)<br/>[Overall survival] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>552<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>403 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>324 per 1000</b><br/>(266 to 394) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease‐free survival (DFS)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No randomised controlled trials reported on disease‐free survival in PMRT women with low‐volume axillary disease. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to progression</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No randomised controlled trials reported time to progression in PMRT women with low‐volume axillary disease. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Short‐term adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No randomised controlled trials evaluated PMRT short‐term adverse events like erythema, hyperpigmentation and breast oedema. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No randomised controlled trials evaluated the long‐term adverse events of PMRT like lymphoedema, cardiac toxicity, pulmonary toxicity, bone necrosis and development of secondary radiation‐induced cancers. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life (QoL)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No randomised controlled trials measured or reported on the quality of life indicators after PMRT. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>HR:</b> hazard Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_433754310228759346" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_433754310228759346</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Estimated from the no‐PMRT group published Kaplan‐Meier curve in one study (Overgaard 2007).<br/><sup>b</sup> Downgraded quality of evidence by one level due to "serious concern about the risk of bias" originating from inadequate random sequence generation, lack of allocation concealment and not attempting to blind the assessors. <br/><sup>c</sup> Downgraded quality of evidence by one level due to the "serious imprecision" because of uncertainty in confidentially determining the spread of the observed effect in the PMRT group. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) compared to no PMRT in women with breast cancer and one to three positive lymph nodes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/full#CD014463-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014463-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">PMRT versus no PMRT in women with one to three positive lymph nodes</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Locoregional recurrence (LRR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.13, 0.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Overall survival (OS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.60, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Disease‐free survival (DFS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Subdistribution Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.41, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">PMRT versus no PMRT in women with one to three positive lymph nodes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014463.pub2/references#CD014463-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD014463.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD014463-note-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD014463-note-0010">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD014463-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD014463-note-0008">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD014463-note-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="hu#CD014463-note-0009">Magyar</a> </li> <li class="section-language"> <a class="" href="id#CD014463-note-0015">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ko#CD014463-note-0005">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD014463-note-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD014463-note-0004">Português</a> </li> <li class="section-language"> <a class="" href="ro#CD014463-note-0016">Română</a> </li> <li class="section-language"> <a class="" href="th#CD014463-note-0013">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD014463-note-0011">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD014463-note-0012">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014463\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014463\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014463\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014463\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014463\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014463\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014463\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014463\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014463\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014463\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014463\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014463\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014463\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014463\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014463\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014463\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014463\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014463\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=8ranHhTh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014463.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014463.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD014463.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD014463.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014463.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740720136158"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014463.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740720136162"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014463.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918df9cd0da89377',t:'MTc0MDcyMDEzNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 